1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-
| Title | Journal |
|---|---|
| Bromodomain and hedgehog pathway targets in small cell lung cancer. | Cancer letters 20160227 |
| Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. | International journal of biochemistry and molecular biology 20160101 |
| Chemical profiling of the genome with anti-cancer drugs defines target specificities. | Nature chemical biology 20150701 |
| Toxicogenomics profiling of bone marrow from rats treated with topotecan in combination with oxaliplatin: a mechanistic strategy to inform combination toxicity. | Frontiers in genetics 20150101 |
| ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. | Cancer research 20141201 |
| Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines. | Oncology reports 20141101 |
| CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. | Biochemical pharmacology 20140915 |
| The γH2AX assay for genotoxic and nongenotoxic agents: comparison of H2AX phosphorylation with cell death response. | Toxicological sciences : an official journal of the Society of Toxicology 20140701 |
| Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. | The Journal of pharmacology and experimental therapeutics 20140301 |
| Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. | Molecules (Basel, Switzerland) 20140217 |
| Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum. | PloS one 20140101 |
| Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs. | Biochimica et biophysica acta 20130801 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. | Investigational new drugs 20121201 |
| What is new in rhabdomyosarcoma management in children? | Paediatric drugs 20121201 |
| Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. | Cancer 20121115 |
| Anticancer activities of genistein-topotecan combination in prostate cancer cells. | Journal of cellular and molecular medicine 20121101 |
| Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. | Leukemia & lymphoma 20121101 |
| Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. | Journal of pharmaceutical and biomedical analysis 20121101 |
| Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20121101 |
| Camptothecins in tumor homing via an RGD sequence mimetic. | Bioorganic & medicinal chemistry letters 20121015 |
| NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. | Pediatric blood & cancer 20121001 |
| Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. | Journal of pharmaceutical sciences 20121001 |
| Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. | The British journal of ophthalmology 20121001 |
| The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth. | Oncology reports 20121001 |
| Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents. | European journal of medicinal chemistry 20121001 |
| Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. | British journal of cancer 20120925 |
| SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. | Oncogene 20120913 |
| New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. | Journal of medicinal chemistry 20120913 |
| Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. | AJNR. American journal of neuroradiology 20120901 |
| The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. | Molecular cancer therapeutics 20120901 |
| Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901 |
| Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. | Investigational new drugs 20120801 |
| Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. | Anti-cancer drugs 20120801 |
| DNA topoisomerase I drugs and radiotherapy for lung cancer. | Journal of thoracic disease 20120801 |
| Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. | The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20120701 |
| Complete remission after neoadjuvant chemotherapy of an advanced vulvar cancer patient: a case report. | The journal of obstetrics and gynaecology research 20120701 |
| Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma. | International journal of clinical pharmacology and therapeutics 20120701 |
| Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120701 |
| The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. | Neoplasia (New York, N.Y.) 20120701 |
| Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. | Investigative ophthalmology & visual science 20120628 |
| Structural spectroscopy and dynamics of inter- and intramolecular H-bonding interactions of topotecan, a potent anticancer drug, in organic solvents and in aqueous solution. | The journal of physical chemistry. B 20120628 |
| Chemotherapy for brain metastases from small cell lung cancer. | The Cochrane database of systematic reviews 20120613 |
| Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. | Journal of controlled release : official journal of the Controlled Release Society 20120610 |
| The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. | Investigational new drugs 20120601 |
| Loading profile of topotecan into polyvinyl alcohol microspheres (DC Bead™) over a 7-day period. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120601 |
| Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. | Cancer metastasis reviews 20120601 |
| Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). | Leukemia & lymphoma 20120601 |
| ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications. | International journal of oncology 20120601 |
| Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. | Angiogenesis 20120601 |
| The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. | Oncology reports 20120601 |
| Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. | Cancer biology & therapy 20120601 |
| Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors. | Chemistry & biodiversity 20120601 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. | Biochemical pharmacology 20120515 |
| Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media. | Chemical communications (Cambridge, England) 20120504 |
| A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. | Journal of the National Cancer Institute 20120502 |
| A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer. | Disease models & mechanisms 20120501 |
| A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. | Oncotarget 20120501 |
| [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department]. | Revue des maladies respiratoires 20120501 |
| Small cell lung cancer metastasizing to the colon in a colovesicular fistula in the setting of diverticulitis. | The American surgeon 20120501 |
| 3'-5' phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo. | The Biochemical journal 20120415 |
| Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. | Journal of medicinal chemistry 20120412 |
| Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411 |
| A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. | Investigational new drugs 20120401 |
| In vitro antifungal activity of DNA topoisomerase inhibitors. | Medical mycology 20120401 |
| A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. | Gynecologic oncology 20120401 |
| Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. | Anti-cancer drugs 20120401 |
| Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster. | Pharmacogenetics and genomics 20120401 |
| Topotecan hydrochloride effects on retinal vessels in newborn rats. | Histology and histopathology 20120401 |
| Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials. | Journal of chemotherapy (Florence, Italy) 20120401 |
| Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors. | Bioorganic & medicinal chemistry letters 20120315 |
| Identification of modulators of hair cell regeneration in the zebrafish lateral line. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20120307 |
| Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. | Oncogene 20120301 |
| Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). | Pediatric blood & cancer 20120301 |
| An unusual case of congenital primitive neuroectodermal tumor with ocular metastasis. | Journal of pediatric hematology/oncology 20120301 |
| Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. | Gynecologic oncology 20120301 |
| Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. | Molecular cancer therapeutics 20120301 |
| In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20120301 |
| Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. | The Journal of pharmacy and pharmacology 20120301 |
| DNA damage by X-rays and their impact on replication processes. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20120301 |
| First-line chemotherapy in epithelial ovarian cancer. | Clinical obstetrics and gynecology 20120301 |
| ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties. | Chinese journal of cancer 20120301 |
| Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial. | Anticancer research 20120301 |
| In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity. | International journal of pharmaceutics 20120227 |
| Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. | Cancer 20120215 |
| Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. | The Journal of biological chemistry 20120203 |
| Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. | Pediatric blood & cancer 20120201 |
| Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). | Annals of oncology : official journal of the European Society for Medical Oncology 20120201 |
| Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. | Lung cancer (Amsterdam, Netherlands) 20120201 |
| Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. | Retina (Philadelphia, Pa.) 20120201 |
| A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradient. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120201 |
| Binding interactions of water-soluble camptothecin derivatives with bovine serum albumin. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20120201 |
| Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. | Biomaterials 20120201 |
| Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins. | Biochemical pharmacology 20120201 |
| Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. | APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120201 |
| Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. | Anticancer research 20120201 |
| Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy. | Archives of ophthalmology (Chicago, Ill. : 1960) 20120201 |
| Silenced genes turned on to treat Angelman's syndrome. | Lab animal 20120120 |
| Fluorescence properties of the Na⁺/H⁺exchanger inhibitor HMA (5-(N,N-hexamethylene)amiloride) are modulated by intracellular pH. | European journal of histochemistry : EJH 20120120 |
| Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. | Nature 20120112 |
| Large-cell neuroendocrine carcinoma of the cervix. | Rare tumors 20120102 |
| Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. | Journal of oncology 20120101 |
| Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120101 |
| Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. | Journal of biomedicine & biotechnology 20120101 |
| Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. | Yonsei medical journal 20120101 |
| Greco-arab and islamic herbal-derived anticancer modalities: from tradition to molecular mechanisms. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Volumetric and MGMT parameters in glioblastoma patients: survival analysis. | BMC cancer 20120101 |
| Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development. | Journal of oncology 20120101 |
| Ovarian cancer: opportunity for targeted therapy. | Journal of oncology 20120101 |
| Integrin inhibitors as a therapeutic agent for ovarian cancer. | Journal of oncology 20120101 |
| A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. | Cell death & disease 20120101 |
| Intrastriatal convection-enhanced delivery results in widespread perivascular distribution in a pre-clinical model. | Fluids and barriers of the CNS 20120101 |
| Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting. | International journal of nanomedicine 20120101 |
| Intraocular hemorrhage after intra-arterial chemotherapy for retinoblastoma in sickle cell trait. | The open ophthalmology journal 20120101 |
| Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin. | Journal of amino acids 20120101 |
| Therapeutic strategies in epithelial ovarian cancer. | Journal of experimental & clinical cancer research : CR 20120101 |
| BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. | Journal of gynecologic oncology 20120101 |
| Major clinical research advances in gynecologic cancer in 2011. | Journal of gynecologic oncology 20120101 |
| Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. | International journal of nanomedicine 20120101 |
| Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. | International journal of nanomedicine 20120101 |
| Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. | PloS one 20120101 |
| A genome-wide study of cytogenetic changes in colorectal cancer using SNP microarrays: opportunities for future personalized treatment. | PloS one 20120101 |
| Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. | PloS one 20120101 |
| Advances in using PARP inhibitors to treat cancer. | BMC medicine 20120101 |
| Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma. | BMC cancer 20120101 |
| Inhibition of ERβ induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines. | PloS one 20120101 |
| PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose. | PloS one 20120101 |
| Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. | BMC infectious diseases 20120101 |
| Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. | PloS one 20120101 |
| Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. | Chemotherapy research and practice 20120101 |
| Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. | Journal of drug delivery 20120101 |
| Acetylcholinesterase involvement in apoptosis. | Frontiers in molecular neuroscience 20120101 |
| Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. | PloS one 20120101 |
| A multimodal approach to the management of neuroendocrine tumour liver metastases. | International journal of hepatology 20120101 |
| Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease. | ISRN oncology 20120101 |
| Brain metastases from endometrial carcinoma. | ISRN oncology 20120101 |
| Comparison of three a-priori models in the prediction of serum lithium concentration. | Indian journal of pharmacology 20120101 |
| Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. | PloS one 20120101 |
| Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. | PloS one 20120101 |
| Novel therapies in glioblastoma. | Neurology research international 20120101 |
| Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. | PloS one 20120101 |
| Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. | PloS one 20120101 |
| Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. | Molecular medicine (Cambridge, Mass.) 20120101 |
| An overview of the evidence and mechanisms of herb-drug interactions. | Frontiers in pharmacology 20120101 |
| Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes. | PloS one 20120101 |
| A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. | PloS one 20120101 |
| Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. | Clinical sarcoma research 20120101 |
| Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. | Clinical sarcoma research 20120101 |
| Mitochondria: redox metabolism and dysfunction. | Biochemistry research international 20120101 |
| Inhaled chemotherapy in lung cancer: future concept of nanomedicine. | International journal of nanomedicine 20120101 |
| Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. | Sarcoma 20120101 |
| Combination drug delivery approaches in metastatic breast cancer. | Journal of drug delivery 20120101 |
| Madarosis: a marker of many maladies. | International journal of trichology 20120101 |
| [Studies by means of 1H NMR spectroscopy of complex formation of aromatic biologically active compounds with antibiotic topotecan]. | Ukrains'kyi biokhimichnyi zhurnal (1999 ) 20120101 |
| The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm. | Frontiers in oncology 20120101 |
| The chemotherapeutic potential of Terminalia ferdinandiana: Phytochemistry and bioactivity. | Pharmacognosy reviews 20120101 |
| Current and emerging pharmacotherapies for primary CNS lymphoma. | Clinical Medicine Insights. Oncology 20120101 |
| Deletion of HIF-1α partially rescues the abnormal hyaloid vascular system in Cited2 conditional knockout mouse eyes. | Molecular vision 20120101 |
| Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report. | Case reports in oncology 20120101 |
| Nucleolin inhibits G4 oligonucleotide unwinding by Werner helicase. | PloS one 20120101 |
| Namitecan: a hydrophilic camptothecin with a promising preclinical profile. | Current medicinal chemistry 20120101 |
| An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. | Case reports in medicine 20120101 |
| In vitro chemosensitivity using the histoculture drug response assay in human epithelial ovarian cancer. | Acta medica Okayama 20120101 |
| DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. | Current medicinal chemistry 20120101 |
| Topotecan and cyclophosphamide in adults with relapsed sarcoma. | Sarcoma 20120101 |
| Weekly topotecan for recurrent small cell lung cancer - a retrospective Anatolian Medical Oncology Group study. | Asian Pacific journal of cancer prevention : APJCP 20120101 |
| The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment. | PloS one 20120101 |
| EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. | PloS one 20120101 |
| A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. | PloS one 20120101 |
| Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. | Drugs 20111224 |
| Neurodevelopmental disorders. New hope for a devastating neurological disorder. | Science (New York, N.Y.) 20111223 |
| Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111215 |
| ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. | Oncogene 20111208 |
| Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. | Investigational new drugs 20111201 |
| A phase I study of topotecan and gemcitabine in advanced solid tumors. | Investigational new drugs 20111201 |
| High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate. | The Journal of surgical research 20111201 |
| A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. | Medical oncology (Northwood, London, England) 20111201 |
| A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. | International journal of clinical oncology 20111201 |
| Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. | Neurosurgery 20111201 |
| Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. | Journal of neuro-oncology 20111201 |
| Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. | Cancer gene therapy 20111201 |
| Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. | Neuro-oncology 20111201 |
| Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer. | Expert opinion on drug metabolism & toxicology 20111201 |
| Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. | Gynecologic oncology 20111201 |
| Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. | Cell cycle (Georgetown, Tex.) 20111201 |
| The clinical outcomes of proton beam radiation therapy for retinoblastomas that were resistant to chemotherapy and focal treatment. | Korean journal of ophthalmology : KJO 20111201 |
| Pilot study of a pediatric metronomic 4-drug regimen. | Oncotarget 20111201 |
| Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. | Cell death & disease 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. | Journal of chemotherapy (Florence, Italy) 20111201 |
| Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases. | Cancer research and treatment : official journal of Korean Cancer Association 20111201 |
| Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel. | Journal of controlled release : official journal of the Controlled Release Society 20111130 |
| Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120 |
| Determining the best dose for the individual patient. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120 |
| MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. | European journal of pharmacology 20111116 |
| Small-cell lung cancer. | Lancet (London, England) 20111112 |
| Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport. | Computer methods and programs in biomedicine 20111101 |
| Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. | Annals of oncology : official journal of the European Society for Medical Oncology 20111101 |
| Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support. | Leukemia & lymphoma 20111101 |
| Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. | Gynecologic oncology 20111101 |
| [Molecular determinants of response to topoisomerase I inhibitors]. | Bulletin du cancer 20111101 |
| A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. | Lung cancer (Amsterdam, Netherlands) 20111001 |
| Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. | Chinese journal of cancer 20111001 |
| Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. | Anticancer research 20111001 |
| Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. | Oncotarget 20111001 |
| Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. | Oncotarget 20111001 |
| Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110901 |
| Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. | Angiogenesis 20110901 |
| Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer. | Cancer biology & therapy 20110901 |
| Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110901 |
| Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. | Cancer research 20110901 |
| Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. | Seminars in nuclear medicine 20110901 |
| An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers. | PLoS computational biology 20110901 |
| ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. | Journal of the National Cancer Institute 20110817 |
| Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D. | Bioorganic & medicinal chemistry 20110815 |
| Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. | Cancer 20110815 |
| Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. | Cancer chemotherapy and pharmacology 20110801 |
| Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. | Journal of neuro-oncology 20110801 |
| Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. | Gynecologic oncology 20110801 |
| Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. | Gynecologic oncology 20110801 |
| Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II. | Archivum immunologiae et therapiae experimentalis 20110801 |
| Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110801 |
| Quantification of the interceptor action of caffeine on the in vitro biological effect of the anti-tumour agent topotecan. | European biophysics journal : EBJ 20110801 |
| Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. | Neuro-oncology 20110801 |
| Management strategies for recurrent platinum-resistant ovarian cancer. | Drugs 20110730 |
| Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. | Journal of medicinal chemistry 20110728 |
| Treatment for advanced cervical cancer: impact on quality of life. | Critical reviews in oncology/hematology 20110701 |
| Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. | Journal of neuro-oncology 20110701 |
| Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. | Gynecologic oncology 20110701 |
| Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. | Gynecologic oncology 20110701 |
| Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. | Disease models & mechanisms 20110701 |
| Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. | Gynecologic oncology 20110701 |
| Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. | Molecular cancer therapeutics 20110701 |
| Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. | Nuclear medicine and biology 20110701 |
| Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities. | Chemistry & biodiversity 20110701 |
| Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. | Cancer research 20110615 |
| Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. | Investigational new drugs 20110601 |
| A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. | Cancer chemotherapy and pharmacology 20110601 |
| Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. | Lung cancer (Amsterdam, Netherlands) 20110601 |
| Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. | Archives of ophthalmology (Chicago, Ill. : 1960) 20110601 |
| DNA repair: the culprit for tumor-initiating cell survival? | Cancer metastasis reviews 20110601 |
| Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20110601 |
| [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20110601 |
| Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents. | European journal of medicinal chemistry 20110601 |
| Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors. | European journal of medicinal chemistry 20110601 |
| Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. | Cancer research 20110601 |
| Periocular topotecan for intraocular retinoblastoma. | Archives of ophthalmology (Chicago, Ill. : 1960) 20110601 |
| [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients]. | Ceska gynekologie 20110601 |
| Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. | Cancer chemotherapy and pharmacology 20110501 |
| A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. | Journal of neuro-oncology 20110501 |
| Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. | Cancer treatment reviews 20110501 |
| New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. | Archives of gynecology and obstetrics 20110501 |
| Electrochemical detection of anticancer drug topotecan using nano-acetylene black film. | Colloids and surfaces. B, Biointerfaces 20110501 |
| Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? | European journal of clinical pharmacology 20110501 |
| Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110501 |
| Trabectedin for the treatment of relapsed ovarian cancer. | Health technology assessment (Winchester, England) 20110501 |
| A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. | Clinical lung cancer 20110501 |
| Early toxicity predicts long-term survival in high-grade glioma. | British journal of cancer 20110426 |
| The solvolysis of topotecan in alcohols and acetic anhydride. | Bioorganic & medicinal chemistry letters 20110415 |
| Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. | Journal of medicinal chemistry 20110414 |
| Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. | Molecular pharmaceutics 20110404 |
| Sialoblastoma- long-term follow-up and remission for a rare salivary malignancy. | Rare tumors 20110404 |
| Second-line chemotherapy for small-cell lung cancer (SCLC). | Cancer treatment reviews 20110401 |
| Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. | Bone marrow transplantation 20110401 |
| Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. | Brain tumor pathology 20110401 |
| Synthesis and antitumor activity of 10-arylcamptothecin derivatives. | Bioorganic & medicinal chemistry letters 20110401 |
| The use of convection-enhanced delivery with liposomal toxins in neurooncology. | Toxins 20110401 |
| Resectable pancreatic small cell carcinoma. | Rare tumors 20110330 |
| 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. | Journal of medicinal chemistry 20110324 |
| The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. | Cancer 20110315 |
| Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature. | Archives of gynecology and obstetrics 20110301 |
| A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. | Japanese journal of clinical oncology 20110301 |
| High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. | Pediatric blood & cancer 20110301 |
| Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. | European journal of cancer (Oxford, England : 1990) 20110301 |
| A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). | Gynecologic oncology 20110301 |
| Recent advances in anti-angiogenic therapy of cancer. | Oncotarget 20110301 |
| Multifaceted chemotherapy for trilateral retinoblastoma. | Archives of ophthalmology (Chicago, Ill. : 1960) 20110301 |
| A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. | Clinical therapeutics 20110301 |
| Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. | Biochemistry 20110208 |
| Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. | Archives of gynecology and obstetrics 20110201 |
| Phase I study of topotecan and cisplatin in patients with small cell lung cancer. | Japanese journal of clinical oncology 20110201 |
| Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| Physiologically based pharmacokinetic model for topotecan in mice. | Journal of pharmacokinetics and pharmacodynamics 20110201 |
| Advances in nano drugs for cancer chemotherapy. | Current cancer drug targets 20110201 |
| [Treatment of small-cell lung cancer]. | Der Internist 20110201 |
| A Blm-Recql5 partnership in replication stress response. | Journal of molecular cell biology 20110201 |
| Anticancer and anti-inflammatory activities of shallot (Allium ascalonicum) extract. | Archives of medical science : AMS 20110201 |
| PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. | Oncogene 20110127 |
| Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. | Proceedings of the National Academy of Sciences of the United States of America 20110125 |
| Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110120 |
| Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. | Cancer 20110115 |
| Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. | Biochemical pharmacology 20110115 |
| 3-Arylisoquinolines as novel topoisomerase I inhibitors. | Bioorganic & medicinal chemistry 20110115 |
| Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110110 |
| Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20110101 |
| Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. | Annals of oncology : official journal of the European Society for Medical Oncology 20110101 |
| Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. | Acta paediatrica (Oslo, Norway : 1992) 20110101 |
| Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report. | Anti-cancer drugs 20110101 |
| High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. | European journal of cancer (Oxford, England : 1990) 20110101 |
| An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. | Gynecologic oncology 20110101 |
| Detection of DNA strand breaks in apoptotic cells by flow- and image-cytometry. | Methods in molecular biology (Clifton, N.J.) 20110101 |
| Intracellular and extracellular microRNAs in breast cancer. | Clinical chemistry 20110101 |
| A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. | Journal of pediatric hematology/oncology 20110101 |
| A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. | Pediatric blood & cancer 20110101 |
| Current therapeutic approaches in metastatic and recurrent ewing sarcoma. | Sarcoma 20110101 |
| Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. | Sarcoma 20110101 |
| Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. | PloS one 20110101 |
| The use of endophytes to obtain bioactive compounds and their application in biotransformation process. | Biotechnology research international 20110101 |
| High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review. | PloS one 20110101 |
| Bevacizumab in the treatment of ovarian cancer. | Biologics : targets & therapy 20110101 |
| Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. | BMC biotechnology 20110101 |
| From antiangiogenesis to hypoxia: current research and future directions. | Cancer management and research 20110101 |
| Characteristics of human Ewing/PNET sarcoma models. | Annals of Saudi medicine 20110101 |
| Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway. | PloS one 20110101 |
| An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. | Journal of Cancer 20110101 |
| miRNA Biomarkers in Breast Cancer Detection and Management. | Journal of Cancer 20110101 |
| Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. | PloS one 20110101 |
| Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride. | Clinical Medicine Insights. Oncology 20110101 |
| Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. | Journal of hematology & oncology 20110101 |
| Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions. | Sarcoma 20110101 |
| Multiple myeloma emerging after prolonged gefitinib treatment for non-small cell lung carcinoma. | Case reports in oncology 20110101 |
| Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. | Breast cancer research : BCR 20110101 |
| Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. | Oncology research 20110101 |
| In vitro antiproliferative activity of partially purified Trigona laeviceps propolis from Thailand on human cancer cell lines. | BMC complementary and alternative medicine 20110101 |
| Mitochondrial dysfunction in Trypanosoma cruzi: the role of Serratia marcescens prodigiosin in the alternative treatment of Chagas disease. | Parasites & vectors 20110101 |
| Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. | PloS one 20110101 |
| Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. | Journal of translational medicine 20110101 |
| Long-term topotecan therapy in recurrent or persistent ovarian cancer. | European journal of gynaecological oncology 20110101 |
| New Topoisomerase I mutations are associated with resistance to camptothecin. | Molecular cancer 20110101 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. | BMC cancer 20110101 |
| Current developments in the therapy of protozoan infections. | The open medicinal chemistry journal 20110101 |
| Myelodysplastic syndrome and histone deacetylase inhibitors: 'to be or not to be acetylated'? | Journal of biomedicine & biotechnology 20110101 |
| A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors. | Current chemical genomics 20110101 |
| Transport processes of radiopharmaceuticals and -modulators. | Radiation oncology (London, England) 20110101 |
| Changes of constituents and activity to apoptosis and cell cycle during fermentation of tea. | International journal of molecular sciences 20110101 |
| Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. | PloS one 20110101 |
| Solitary Internal Mammary Lymph Node Metastases Detected by F-FDG-PET/CT in Ovarian Cancer. | Case reports in oncology 20110101 |
| Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. | PloS one 20110101 |
| Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. | European journal of medical research 20110101 |
| The use of erlotinib in daily practice: a study on adherence and patients' experiences. | BMC cancer 20110101 |
| Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. | PloS one 20110101 |
| Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. | Cancer management and research 20110101 |
| A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy. | Case reports in oncology 20110101 |
| Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. | BMC medical genomics 20110101 |
| Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer. | BMC cancer 20110101 |
| iAB-RBC-283: A proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological states. | BMC systems biology 20110101 |
| Leaf Extracts of Calocedrus formosana (Florin) Induce G2/M Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. | Obstetrics and gynecology international 20110101 |
| In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. | Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research 20110101 |
| Clinical therapeutics in pregnancy. | Journal of biomedicine & biotechnology 20110101 |
| Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. | Cancer management and research 20110101 |
| A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. | BMC cancer 20110101 |
| Drug therapy for hereditary cancers. | Hereditary cancer in clinical practice 20110101 |
| Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts. | Arthritis research & therapy 20110101 |
| Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. | Oncology 20110101 |
| Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer. | Clinical Medicine Insights. Oncology 20110101 |
| A novel preparation method for camptothecin (CPT) loaded folic acid conjugated dextran tumor-targeted nanoparticles. | International journal of molecular sciences 20110101 |
| Regulation of apoptotic effects by erythrocarpine E, a cytotoxic limonoid from Chisocheton erythrocarpus in HSC-4 human oral cancer cells. | PloS one 20110101 |
| Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? | Breast cancer research : BCR 20110101 |
| Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan. | Oxidative medicine and cellular longevity 20110101 |
| A method for efficient calculation of diffusion and reactions of lipophilic compounds in complex cell geometry. | PloS one 20110101 |
| Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives. | PloS one 20110101 |
| Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. | OncoTargets and therapy 20110101 |
| Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. | Oxidative medicine and cellular longevity 20110101 |
| Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. | Journal of hematology & oncology 20110101 |
| Meningitic Escherichia coli K1 penetration and neutrophil transmigration across the blood-brain barrier are modulated by alpha7 nicotinic receptor. | PloS one 20110101 |
| Exploring DNA topoisomerase I ligand space in search of novel anticancer agents. | PloS one 20110101 |
| Platinum resistance in breast and ovarian cancer cell lines. | Journal of experimental & clinical cancer research : CR 20110101 |
| Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway. | PloS one 20110101 |
| Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. | BMC cancer 20110101 |
| The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. | PloS one 20110101 |
| Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. | PloS one 20110101 |
| Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. | Obstetrics and gynecology international 20110101 |
| The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. | BMC cancer 20110101 |
| Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole. | Fluids and barriers of the CNS 20110101 |
| Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review. | European journal of medical research 20110101 |
| Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. | Bone marrow research 20110101 |
| Choroid plexus transport: gene deletion studies. | Fluids and barriers of the CNS 20110101 |
| Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. | International journal of nanomedicine 20110101 |
| Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. | PloS one 20110101 |
| Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. | BMC cancer 20110101 |
| Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. | Journal of experimental & clinical cancer research : CR 20110101 |
| A rare bladder cancer--small cell carcinoma: review and update. | Orphanet journal of rare diseases 20110101 |
| A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. | Journal of hematology & oncology 20110101 |
| Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. | Cancer informatics 20110101 |
| Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective. | ISRN oncology 20110101 |
| Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. | PloS one 20110101 |
| A very rare adult case with neuroblastoma. | Case reports in oncology 20110101 |
| Targeting hypoxic tumour cells to overcome metastasis. | BMC cancer 20110101 |
| A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens. | International journal of nanomedicine 20110101 |
| Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. | Journal of ovarian research 20110101 |
| Attenuation of cytotoxic natural product DNA intercalating agents by caffeine. | Scientia pharmaceutica 20110101 |
| The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. | International journal of nanomedicine 20110101 |
| Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. | International journal of hepatology 20110101 |
| Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model. | International journal of hepatology 20110101 |
| Enucleated eyes after failed intra-arterial infusion of chemotherapy for unilateral retinoblastoma: histopathologic evaluation of vitreous seeding. | Clinical ophthalmology (Auckland, N.Z.) 20110101 |
| Development of derivatives of 3, 3'-diindolylmethane as potent Leishmania donovani bi-subunit topoisomerase IB poisons. | PloS one 20110101 |
| Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression. | Journal of oncology 20110101 |
| Radiotherapy and 'new' drugs-new side effects? | Radiation oncology (London, England) 20110101 |
| Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. | Cancer cell international 20110101 |
| Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. | PloS one 20110101 |
| Exophthalmos as a first manifestation of small cell lung cancer: a long-term follow-up. | Case reports in ophthalmology 20110101 |
| Monoclonal antibodies in gynecological cancer: a critical point of view. | Clinical & developmental immunology 20110101 |
| [Five year-results of chemoresistance testing in cancer patients]. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101 |
| The state of research into children with cancer across Europe: new policies for a new decade. | Ecancermedicalscience 20110101 |
| Retinoblastoma: Recent trends A mini review based on published literature. | Oman journal of ophthalmology 20110101 |
| Functionally Relevant Residues of Cdr1p: A Multidrug ABC Transporter of Human Pathogenic Candida albicans. | Journal of amino acids 20110101 |
| Multidrug resistance in breast cancer: from in vitro models to clinical studies. | International journal of breast cancer 20110101 |
| Cell death signaling and anticancer therapy. | Frontiers in oncology 20110101 |
| Combined modality approaches in the management of adult glioblastoma. | Frontiers in oncology 20110101 |
| Glutathione s-transferases in pediatric cancer. | Frontiers in oncology 20110101 |
| Investigational approaches for mesothelioma. | Frontiers in oncology 20110101 |
| Outcomes of advanced and recurrent cervical cancer treated with cisplatin and generic topotecan: retrospective analysis in a tertiary care hospital in Thailand. | Journal of gynecologic oncology 20101230 |
| Cancer and renal insufficiency results of the BIRMA study. | British journal of cancer 20101207 |
| Multimodality management for 145 cases of Merkel cell carcinoma. | Medical oncology (Northwood, London, England) 20101201 |
| Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. | International journal of cancer 20101201 |
| Chemoresistance testing of human ovarian cancer cells and its in vitro model. | Toxicology in vitro : an international journal published in association with BIBRA 20101201 |
| Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. | Gynecologic oncology 20101201 |
| Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. | Cancer biology & therapy 20101201 |
| Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101201 |
| The DAC system and associations with acute leukemias and myelodysplastic syndromes. | Investigational new drugs 20101201 |
| Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. | Molecular cancer therapeutics 20101201 |
| Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins. | Molecular cancer therapeutics 20101201 |
| Growth Inhibition and Apoptosis with H31 Metabolites from Marine Bacillus SW31 in Head and Neck Cancer Cells. | Clinical and experimental otorhinolaryngology 20101201 |
| Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101115 |
| Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery. | Bioorganic & medicinal chemistry letters 20101115 |
| Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules. | Bioinformatics (Oxford, England) 20101115 |
| Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin. | Talanta 20101115 |
| Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. | British journal of cancer 20101109 |
| A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. | Cancer chemotherapy and pharmacology 20101101 |
| Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. | European journal of cancer (Oxford, England : 1990) 20101101 |
| Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. | British journal of cancer 20101101 |
| Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor. | Future oncology (London, England) 20101101 |
| [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101101 |
| Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends. | Anti-cancer agents in medicinal chemistry 20101101 |
| Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator? | International journal of pharmaceutics 20101031 |
| Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. | British journal of cancer 20101026 |
| Another confirmation of the inactivity of topotecan in ovarian cancer. | Journal of the National Cancer Institute 20101020 |
| Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. | Journal of the National Cancer Institute 20101020 |
| Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. | European journal of pharmacology 20101010 |
| Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. | Breast cancer research and treatment 20101001 |
| Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. | Cancer chemotherapy and pharmacology 20101001 |
| Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. | European journal of cancer (Oxford, England : 1990) 20101001 |
| Therapy of small cell lung cancer with emphasis on oral topotecan. | Lung cancer (Amsterdam, Netherlands) 20101001 |
| Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. | Gynecologic oncology 20101001 |
| Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101001 |
| Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001 |
| Ewing's sarcoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20101001 |
| Combining cytotoxic and targeted therapies for lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001 |
| Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes. | Journal of controlled release : official journal of the Controlled Release Society 20100915 |
| Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. | Journal of pharmaceutical and biomedical analysis 20100905 |
| Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. | Journal of materials science. Materials in medicine 20100901 |
| A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies. | The oncologist 20100901 |
| Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). | Current drug metabolism 20100901 |
| 7'-Methyl-5'-oxo-2',3'-dihydro-spiro-[1,3-dioxolane-2,1'(5'H)-indolizine]-6'-carbonitrile. | Acta crystallographica. Section E, Structure reports online 20100901 |
| Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009. | Journal of cachexia, sarcopenia and muscle 20100901 |
| A proteomic screen for nucleolar SUMO targets shows SUMOylation modulates the function of Nop5/Nop58. | Molecular cell 20100827 |
| Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. | British journal of cancer 20100824 |
| Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. | British journal of cancer 20100824 |
| Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. | British journal of cancer 20100824 |
| Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820 |
| Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820 |
| Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. | Biochemical pharmacology 20100815 |
| Free energy calculations reveal rotating-ratchet mechanism for DNA supercoil relaxation by topoisomerase IB and its inhibition. | Biophysical journal 20100804 |
| Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. | American journal of clinical oncology 20100801 |
| Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. | Cancer chemotherapy and pharmacology 20100801 |
| Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). | Ophthalmology 20100801 |
| Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan. | Biochemical pharmacology 20100801 |
| Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. | American journal of obstetrics and gynecology 20100801 |
| Topotecan and etoposide combination to test neuroblastoma in pediatric preclinical testing program. | Pediatric blood & cancer 20100801 |
| Topotecan dynamics, tautomerism and reactivity--1H/13C NMR and ESI MS study. | Magnetic resonance in chemistry : MRC 20100801 |
| Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. | Assay and drug development technologies 20100801 |
| Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. | Molecular cancer therapeutics 20100801 |
| [Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells]. | Zhongguo shi yan xue ye xue za zhi 20100801 |
| Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. | Pediatric blood & cancer 20100715 |
| Experiment on the factors for enhancing the susceptibility of cancer cells to chemotherapeutic drug by ultrasound microbubbles. | Journal of drug targeting 20100701 |
| Trifluoromethyl-promoted homocamptothecins: synthesis and biological activity. | European journal of medicinal chemistry 20100701 |
| Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. | Experimental eye research 20100701 |
| Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38. | European journal of medicinal chemistry 20100701 |
| Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. | Clinical lung cancer 20100701 |
| Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. | Anticancer research 20100701 |
| Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. | British journal of cancer 20100629 |
| Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. | Cancer 20100615 |
| Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. | Molecular pharmaceutics 20100607 |
| A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma. | Medical oncology (Northwood, London, England) 20100601 |
| Review role of topotecan in gynaecological cancers: current indications and perspectives. | Critical reviews in oncology/hematology 20100601 |
| Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I. | European journal of medicinal chemistry 20100601 |
| A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. | Gynecologic oncology 20100601 |
| Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. | Cancer research 20100601 |
| A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100601 |
| The war on cancer: have we won the battle but lost the war? | Oncotarget 20100601 |
| Solvent effects on the valence UV-vis absorption spectra of topotecan anticancer drug in aqueous solution at room temperature: a nanoseconds time-scale TD-DFT/MD computational study. | The journal of physical chemistry. B 20100527 |
| Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue. | Journal of neuro-oncology 20100501 |
| High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. | Journal of neuro-oncology 20100501 |
| Initial testing of topotecan by the pediatric preclinical testing program. | Pediatric blood & cancer 20100501 |
| Achievements and unmet needs in the management of advanced ovarian cancer. | Gynecologic oncology 20100501 |
| Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. | Annals of surgical oncology 20100501 |
| Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. | Pediatric blood & cancer 20100501 |
| Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities. | Bioorganic & medicinal chemistry 20100501 |
| Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. | Health technology assessment (Winchester, England) 20100501 |
| [Hematological toxicity of some combined chemotherapy schemes involving aranoza]. | Eksperimental'naia i klinicheskaia farmakologiia 20100501 |
| [Resistance/sensitivity in vitro in ovarian cancer patients]. | Ceska gynekologie 20100501 |
| Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. | British journal of cancer 20100427 |
| Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. | Biochemical pharmacology 20100415 |
| Topotecan in second-line treatment of small-cell lung cancer--how it works in our daily clinical practice? | Current drug safety 20100401 |
| Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. | Cancer chemotherapy and pharmacology 20100401 |
| Episcleral implants for topotecan delivery to the posterior segment of the eye. | Investigative ophthalmology & visual science 20100401 |
| Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. | Annals of oncology : official journal of the European Society for Medical Oncology 20100401 |
| Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. | Pediatric blood & cancer 20100401 |
| Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. | Molecular cancer therapeutics 20100401 |
| Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. | Molecular cancer therapeutics 20100401 |
| Flow-based cytometric analysis of cell cycle via simulated cell populations. | PLoS computational biology 20100401 |
| Phytochemicals in cancer prevention and therapy: truth or dare? | Toxins 20100401 |
| [Immediate versus delayed topotecan after first-line therapy in small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100320 |
| Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. | Journal of medicinal chemistry 20100311 |
| Pharmacotherapy options for locally advanced and advanced cervical cancer. | Drugs 20100305 |
| Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. | Bone marrow transplantation 20100301 |
| Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20100301 |
| A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. | Journal of clinical pharmacology 20100301 |
| The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. | European journal of haematology 20100301 |
| The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. | Molecular pharmacology 20100301 |
| A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells. | Pharmaceutical research 20100301 |
| Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100301 |
| Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100301 |
| Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. | Archives of ophthalmology (Chicago, Ill. : 1960) 20100301 |
| The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20100301 |
| Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. | British journal of cancer 20100216 |
| Treatment options for small cell lung cancer - do we have more choice? | British journal of cancer 20100216 |
| Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. | Biochemical pharmacology 20100215 |
| Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. | Cancer research 20100215 |
| Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. | British journal of cancer 20100202 |
| Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. | Anti-cancer drugs 20100201 |
| Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. | International journal of oncology 20100201 |
| Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100201 |
| Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). | Annals of oncology : official journal of the European Society for Medical Oncology 20100201 |
| Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. | The journal of obstetrics and gynaecology research 20100201 |
| The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. | Clinical advances in hematology & oncology : H&O 20100201 |
| Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I. | The Biochemical journal 20100115 |
| Development of a highly stable and targetable nanoliposomal formulation of topotecan. | Journal of controlled release : official journal of the Controlled Release Society 20100104 |
| MicroRNAs as Novel Biomarkers for Breast Cancer. | Journal of oncology 20100101 |
| Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. | British journal of haematology 20100101 |
| Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. | The Journal of pharmacology and experimental therapeutics 20100101 |
| Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. | Pediatric blood & cancer 20100101 |
| Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. | Anti-cancer drugs 20100101 |
| Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. | Gynecologic oncology 20100101 |
| Endophytic fungal strains of Fusarium solani, from Apodytes dimidiata E. Mey. ex Arn (Icacinaceae) produce camptothecin, 10-hydroxycamptothecin and 9-methoxycamptothecin. | Phytochemistry 20100101 |
| Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. | Cancer 20100101 |
| Controversies in the treatment of advanced stages of small cell lung cancer. | Frontiers of radiation therapy and oncology 20100101 |
| A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. | BMC medicine 20100101 |
| Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. | PloS one 20100101 |
| Targeting the EGF receptor for ovarian cancer therapy. | Journal of oncology 20100101 |
| Treatment for recurrent ovarian cancer-at first relapse. | Journal of oncology 20100101 |
| A current review of targeted therapeutics for ovarian cancer. | Journal of oncology 20100101 |
| Antivascular therapy for epithelial ovarian cancer. | Journal of oncology 20100101 |
| miR-21: an oncomir on strike in prostate cancer. | Molecular cancer 20100101 |
| Targeted therapy in ovarian cancer. | Journal of oncology 20100101 |
| Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20100101 |
| Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? | Obstetrics and gynecology international 20100101 |
| Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. | Obstetrics and gynecology international 20100101 |
| BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer. | Journal of oncology 20100101 |
| Identification of functional modules that correlate with phenotypic difference: the influence of network topology. | Genome biology 20100101 |
| Small-cell carcinoma of the ovary with breast metastases: a case report. | Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101 |
| PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs. | Cellular oncology : the official journal of the International Society for Cellular Oncology 20100101 |
| Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. | Journal of hematology & oncology 20100101 |
| Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. | BMC cancer 20100101 |
| Quality of life measurement in women with cervical cancer: implications for Chinese cervical cancer survivors. | Health and quality of life outcomes 20100101 |
| Cytotoxicity of Atriplex confertifolia. | Journal of toxicology 20100101 |
| MicroRNAs and their target gene networks in breast cancer. | Breast cancer research : BCR 20100101 |
| Cell-specific expression of tryptophan decarboxylase and 10-hydroxygeraniol oxidoreductase, key genes involved in camptothecin biosynthesis in Camptotheca acuminata Decne (Nyssaceae). | BMC plant biology 20100101 |
| Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. | PloS one 20100101 |
| Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice. | BMC molecular biology 20100101 |
| Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. | Journal of oncology 20100101 |
| Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. | Breast cancer research : BCR 20100101 |
| [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report]. | Pneumonologia i alergologia polska 20100101 |
| Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. | PloS one 20100101 |
| Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. | Journal of oncology 20100101 |
| Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. | BMC cancer 20100101 |
| Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex. | PloS one 20100101 |
| Controversies in the management of endometrial carcinoma. | Obstetrics and gynecology international 20100101 |
| Anti-angiogenesis therapies: their potential in cancer management. | OncoTargets and therapy 20100101 |
| Hypoxia-specific targets in cancer therapy: role of splice variants. | BMC medicine 20100101 |
| Expression of chemoresistance-related genes and heat shock protein 72 in hyperthermic isolated limb perfusion of malignant melanoma: an experimental study. | Journal of oncology 20100101 |
| Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. | Journal of medical case reports 20100101 |
| Personalized therapies in the cancer 'omics' era. | Molecular cancer 20100101 |
| HSP70: a promising target for laryngeal carcinoma radiaotherapy by inhibiting cleavage and degradation of nucleolin. | Journal of experimental & clinical cancer research : CR 20100101 |
| Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. | Breast cancer research : BCR 20100101 |
| Characterization of immortalized choroid plexus epithelial cell lines for studies of transport processes across the blood-cerebrospinal fluid barrier. | Cerebrospinal fluid research 20100101 |
| Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. | Marine drugs 20100101 |
| Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. | BMC cancer 20100101 |
| Recent advances in the treatment of acute myeloid leukemia. | F1000 medicine reports 20100101 |
| Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. | PloS one 20100101 |
| H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. | Journal of nucleic acids 20100101 |
| Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination. | PloS one 20100101 |
| Fluorescence in situ hybridization in combination with the comet assay and micronucleus test in genetic toxicology. | Molecular cytogenetics 20100101 |
| Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma. | Middle East African journal of ophthalmology 20100101 |
| Molecular pathology of retinoblastoma. | Middle East African journal of ophthalmology 20100101 |
| A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. | Radiation oncology (London, England) 20100101 |
| Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. | PloS one 20100101 |
| Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. | Metal-based drugs 20100101 |
| Chemotherapy in Ewing's sarcoma. | Indian journal of orthopaedics 20100101 |
| Nano to micro delivery systems: targeting angiogenesis in brain tumors. | Journal of angiogenesis research 20100101 |
| PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. | F1000 biology reports 20100101 |
| Pegylated liposomal doxorubicin in the management of ovarian cancer. | Therapeutics and clinical risk management 20100101 |
| Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients. | International journal of nanomedicine 20100101 |
| Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. | Molecular cytogenetics 20100101 |
| Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats. | International journal of nanomedicine 20100101 |
| GADD45β Determines Chemoresistance and Invasive Growth of Side Population Cells of Human Embryonic Carcinoma. | Stem cells international 20100101 |
| Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. | BMC cancer 20100101 |
| Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. | Oncology 20100101 |
| Human TOP1 residues implicated in species specificity of HIV-1 infection are required for interaction with BTBD2, and RNAi of BTBD2 in old world monkey and human cells increases permissiveness to HIV-1 infection. | Virology journal 20100101 |
| Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. | Molecular cancer 20100101 |
| Pulmonary lymphangitic carcinomatosis from squamous cell carcinoma of the cervix. | World journal of surgical oncology 20100101 |
| AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. | Oncology research 20100101 |
| Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia. | Hematology/oncology and stem cell therapy 20100101 |
| Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. | Cancer management and research 20100101 |
| Role of bevacizumab therapy in the management of glioblastoma. | Cancer management and research 20100101 |
| Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer. | Cancer management and research 20100101 |
| New developments in treatment of ovarian carcinoma: focus on trabectedin. | Cancer management and research 20100101 |
| Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. | Advances in pharmacological sciences 20100101 |
| Development and Validation of a RP-Ultra performance liquid chromatographic Method for Quantification of Topotecan Hydrochloride in Bulk and Injection Dosage Form. | Indian journal of pharmaceutical sciences 20100101 |
| UK Guidelines for the Management of Bone Sarcomas. | Sarcoma 20100101 |
| Clinical trials and progress with paclitaxel in ovarian cancer. | International journal of women's health 20100101 |
| Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome. | Mediterranean journal of hematology and infectious diseases 20100101 |
| Primary signet ring cell mucinous ovarian carcinoma: a case report and literature review. | Case reports in oncology 20100101 |
| Co-localization of GSTP1 and JNK in transitional cell carcinoma of urinary bladder. | Genetics and molecular biology 20100101 |
| Ayurveda and cancer. | Pharmacognosy research 20100101 |
| Secondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs. | Pharmacognosy reviews 20100101 |
| Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. | British journal of cancer 20091215 |
| Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. | The Journal of pharmacology and experimental therapeutics 20091201 |
| Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. | Gynecologic oncology 20091201 |
| [Place of autologous and allogeneic hematopoietic stem cell transplantation in ovarian cancer]. | Bulletin du cancer 20091201 |
| Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20091201 |
| Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay. | The Tohoku journal of experimental medicine 20091201 |
| Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. | Neoplasia (New York, N.Y.) 20091201 |
| WU Polyomavirus (WUPyV): A Recently Detected Virus Causing Respiratory Disease? | Viruses 20091201 |
| 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. | Journal of medicinal chemistry 20091126 |
| Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. | International journal of cancer 20091115 |
| Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20091101 |
| Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). | Thrombosis research 20091101 |
| Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. | Journal of neuro-oncology 20091101 |
| Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. | Molecular pharmacology 20091101 |
| A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. | Gynecologic oncology 20091101 |
| Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091101 |
| Synthesis and antiproliferative evaluation of 6-arylindeno[1,2-c]quinoline derivatives. | Bioorganic & medicinal chemistry 20091101 |
| ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20091101 |
| Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. | Molecular cancer therapeutics 20091101 |
| Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. | British journal of cancer 20091020 |
| Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. | The Journal of biological chemistry 20091009 |
| Chemotherapy versus best supportive care for extensive small cell lung cancer. | The Cochrane database of systematic reviews 20091007 |
| Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. | British journal of cancer 20091006 |
| Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children. | Leukemia research 20091001 |
| Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. | Investigative ophthalmology & visual science 20091001 |
| Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001 |
| A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. | International journal of radiation oncology, biology, physics 20091001 |
| Chemotherapy: Topotecan or treosulfan--that is the question. | Nature reviews. Clinical oncology 20091001 |
| Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. | Journal of Korean medical science 20091001 |
| New advances in the second-line treatment of small cell lung cancer. | The oncologist 20091001 |
| [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia]. | Zhongguo shi yan xue ye xue za zhi 20091001 |
| [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment]. | Brain and nerve = Shinkei kenkyu no shinpo 20091001 |
| Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. | Journal of medicinal chemistry 20090924 |
| Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. | Cellular and molecular neurobiology 20090901 |
| Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20090901 |
| The role of transporters in the pharmacokinetics of orally administered drugs. | Pharmaceutical research 20090901 |
| Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. | International journal of radiation oncology, biology, physics 20090901 |
| The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system. | International journal of molecular sciences 20090901 |
| Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases. | The Journal of reproductive medicine 20090901 |
| Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. | Interdisciplinary toxicology 20090901 |
| The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. | Cancer letters 20090828 |
| Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. | British journal of cancer 20090818 |
| The role of apoptotic cell death in the radiosensitising effect of gemcitabine. | British journal of cancer 20090818 |
| Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. | Cancer biology & therapy 20090815 |
| Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. | Cancer chemotherapy and pharmacology 20090801 |
| HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. | Journal of cancer research and clinical oncology 20090801 |
| Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). | Gynecologic oncology 20090801 |
| Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. | Gynecologic oncology 20090801 |
| On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. | Bioorganic & medicinal chemistry letters 20090801 |
| 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation. | Bioorganic & medicinal chemistry letters 20090801 |
| Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. | Journal of pediatric hematology/oncology 20090801 |
| Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. | Journal of Korean medical science 20090801 |
| [Effect of topotecan on expression of aquaporin protein 5 and nuclear factor-kappaB in ovarian cancer SKOV3 cells]. | Ai zheng = Aizheng = Chinese journal of cancer 20090801 |
| [Effect of topotecan on MAGE gene expression of HPB-AM cells]. | Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20090801 |
| Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. | Cancer research 20090715 |
| Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours. | British journal of cancer 20090707 |
| Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. | Cancer chemotherapy and pharmacology 20090701 |
| Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. | Cancer chemotherapy and pharmacology 20090701 |
| Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. | Journal of neuro-oncology 20090701 |
| Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. | Biomedical chromatography : BMC 20090701 |
| Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090701 |
| Blasting neuroblastoma using optimal control of chemotherapy. | Mathematical biosciences and engineering : MBE 20090701 |
| Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. | Molecular cancer therapeutics 20090701 |
| Pros and cons for systemic therapy in recurrent ovarian cancer. | Anticancer research 20090701 |
| Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. | Cancer letters 20090628 |
| Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090628 |
| Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. | British journal of cancer 20090616 |
| Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. | Bioorganic & medicinal chemistry letters 20090615 |
| Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. | Journal of cancer research and clinical oncology 20090601 |
| Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. | Journal of neuro-oncology 20090601 |
| Genetic alterations and chemosensitivity profile in newly established human renal collecting duct carcinoma cell lines. | BJU international 20090601 |
| A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. | Gynecologic oncology 20090601 |
| Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090601 |
| DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin. | Protein science : a publication of the Protein Society 20090601 |
| Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii. | Journal of natural products 20090522 |
| Dose escalation methods in phase I cancer clinical trials. | Journal of the National Cancer Institute 20090520 |
| Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. | The Journal of pharmacology and experimental therapeutics 20090501 |
| MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. | Gynecologic oncology 20090501 |
| The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse. | International journal of hematology 20090501 |
| A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090501 |
| Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases. | Acta pharmacologica Sinica 20090501 |
| Novel camptothecin derivatives as topoisomerase I inhibitors. | Expert opinion on therapeutic patents 20090501 |
| Topotecan-induced long-term remission of an advanced endometrial cancer after treatment with cisplatinum, an anthracycline and paclitaxel. | Anticancer research 20090501 |
| [Second-line treatment and targeted therapy of advanced lung cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090501 |
| UV-vis spectra of the anticancer camptothecin family drugs in aqueous solution: specific spectroscopic signatures unraveled by a combined computational and experimental study. | The journal of physical chemistry. B 20090423 |
| Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. | British journal of cancer 20090407 |
| A phase I study of periocular topotecan in children with intraocular retinoblastoma. | Investigative ophthalmology & visual science 20090401 |
| Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones. | European journal of medicinal chemistry 20090401 |
| Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon? | Biomedical chromatography : BMC 20090401 |
| Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. | Drug metabolism and disposition: the biological fate of chemicals 20090401 |
| Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. | Gynecologic oncology 20090401 |
| 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. | Bioorganic & medicinal chemistry 20090401 |
| NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis. | Proteomics 20090401 |
| Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. | Seminars in oncology 20090401 |
| Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. | Expert opinion on pharmacotherapy 20090401 |
| Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20090401 |
| EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. | Anticancer research 20090401 |
| Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320 |
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320 |
| Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. | British journal of cancer 20090310 |
| Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. | International journal of radiation oncology, biology, physics 20090301 |
| Modulation of the physicochemical state of interior agents to prepare controlled release liposomes. | Colloids and surfaces. B, Biointerfaces 20090301 |
| Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan. | Environmental and molecular mutagenesis 20090301 |
| Current role and future aspects of topotecan in relapsed ovarian cancer. | Current medical research and opinion 20090301 |
| Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. | International journal of clinical pharmacology and therapeutics 20090301 |
| Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. | British journal of cancer 20090224 |
| [Comparison of Oral Topotecan/Intravenous Cisplatin (TC) with Intravenous Etoposide/Cisplatin (EP) as First Line Chemotherapy in Untreated Small Cell Lung Cancer Patient.]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20090220 |
| Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. | British journal of cancer 20090210 |
| Topotecan enhances immune clearance of gliomas. | Cancer immunology, immunotherapy : CII 20090201 |
| Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. | American journal of clinical oncology 20090201 |
| Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. | Anti-cancer agents in medicinal chemistry 20090201 |
| [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090201 |
| Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. | Advanced drug delivery reviews 20090131 |
| A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. | British journal of cancer 20090127 |
| Synthesis and antitumor activity of novel 20s-camptothecin analogues. | Bioorganic & medicinal chemistry letters 20090115 |
| Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. | Medical oncology (Northwood, London, England) 20090101 |
| Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. | Journal of clinical pharmacology 20090101 |
| A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. | Gynecologic oncology 20090101 |
| Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. | Medical oncology (Northwood, London, England) 20090101 |
| Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). | Cancer 20090101 |
| Diflomotecan, a promising homocamptothecin for cancer therapy. | Expert opinion on investigational drugs 20090101 |
| Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. | Neoplasia (New York, N.Y.) 20090101 |
| Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. | Theoretical biology & medical modelling 20090101 |
| A literature review of the recent radiotherapy clinical trials in pediatric brain tumors. | Reviews on recent clinical trials 20090101 |
| Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. | Molecular cancer 20090101 |
| The p53-induced Siva-1 plays a significant role in cisplatin-mediated apoptosis. | Journal of carcinogenesis 20090101 |
| Port-site metastasis after laparoscopic extraperitoneal paraaortic lymphadenectomy for stage IIb squamous cell carcinoma of the cervix. | Journal of minimally invasive gynecology 20090101 |
| Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. | Molecular pharmaceutics 20090101 |
| CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. | Molecular cancer 20090101 |
| Cytometric analysis of DNA damage: phosphorylation of histone H2AX as a marker of DNA double-strand breaks (DSBs). | Methods in molecular biology (Clifton, N.J.) 20090101 |
| Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. | PloS one 20090101 |
| Cell survival from chemotherapy depends on NF-kappaB transcriptional up-regulation of coenzyme Q biosynthesis. | PloS one 20090101 |
| Analysis of gene expression profiles in HeLa cells in response to overexpression or siRNA-mediated depletion of NASP. | Reproductive biology and endocrinology : RB&E 20090101 |
| A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. | PloS one 20090101 |
| Outcome of recurrent and metastatic small cell carcinoma of the bladder. | BMC urology 20090101 |
| Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. | BMC cancer 20090101 |
| Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. | Clinical interventions in aging 20090101 |
| Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. | Trials 20090101 |
| Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. | Journal of experimental & clinical cancer research : CR 20090101 |
| The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cells. | Radiation oncology (London, England) 20090101 |
| An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. | Breast cancer research : BCR 20090101 |
| A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. | Journal of hematology & oncology 20090101 |
| Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum. | Journal of biomedicine & biotechnology 20090101 |
| Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. | PloS one 20090101 |
| Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases. | Indian journal of urology : IJU : journal of the Urological Society of India 20090101 |
| Network-assisted protein identification and data interpretation in shotgun proteomics. | Molecular systems biology 20090101 |
| Pegylated liposomal doxorubicin in ovarian cancer. | Therapeutics and clinical risk management 20090101 |
| Networking of differentially expressed genes in human cancer cells resistant to methotrexate. | Genome medicine 20090101 |
| Treatment of recurrent epithelial ovarian cancer. | Therapeutics and clinical risk management 20090101 |
| Cytometric assessment of DNA damage induced by DNA topoisomerase inhibitors. | Methods in molecular biology (Clifton, N.J.) 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. | PloS one 20090101 |
| BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? | Journal of ovarian research 20090101 |
| Rhabdomyosarcoma of the posterior chest wall in a newborn: a case report. | Cases journal 20090101 |
| Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. | Molecular cancer 20090101 |
| Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. | PloS one 20090101 |
| Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model. | Drug design, development and therapy 20090101 |
| Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. | Molecular cancer 20090101 |
| Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. | Health and quality of life outcomes 20090101 |
| A reproducible brain tumour model established from human glioblastoma biopsies. | BMC cancer 20090101 |
| What lies behind serum urate concentration? Insights from genetic and genomic studies. | Genome medicine 20090101 |
| InPACdb--Indian plant anticancer compounds database. | Bioinformation 20090101 |
| Chenopodium album prevents progression of cell growth and enhances cell toxicity in human breast cancer cell lines. | Oxidative medicine and cellular longevity 20090101 |
| Bendamustine in the treatment of non-Hodgkin's lymphomas. | OncoTargets and therapy 20090101 |
| A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment. | Nanoscale research letters 20090101 |
| Update on the utility of prognostic biomarkers in ovarian cancer. | F1000 medicine reports 20090101 |
| Current status of maintenance therapy for advanced ovarian cancer. | International journal of women's health 20090101 |
| Evolving role of cetuximab in the treatment of colorectal cancer. | Cancer management and research 20090101 |
| Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron. | Cancer management and research 20090101 |
| A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin expression by topotecan and hexamethylene bisacetamide. | Molecular medicine reports 20090101 |
| Semi-synthesis and biological activity of gamma-lactones analogs of camptothecin. | Bioorganic & medicinal chemistry letters 20081215 |
| Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. | Gynecologic oncology 20081201 |
| Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. | Pediatric blood & cancer 20081201 |
| WRN protects against topo I but not topo II inhibitors by preventing DNA break formation. | DNA repair 20081201 |
| Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. | Gynecologic oncology 20081201 |
| Glutamate regulates the activity of topoisomerase I in mouse cerebellum. | Molecular neurobiology 20081201 |
| ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. | Cancer science 20081201 |
| Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081201 |
| Management of small-cell lung cancer: incremental changes but hope for the future. | Oncology (Williston Park, N.Y.) 20081130 |
| Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line. | Chemico-biological interactions 20081125 |
| Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120 |
| The role of polyamine architecture on the pharmacological activity of open lactone camptothecin-polyamine conjugates. | Bioconjugate chemistry 20081119 |
| Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081115 |
| Antitumor efficacy testing in rodents. | Journal of the National Cancer Institute 20081105 |
| A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. | Journal of pharmaceutical sciences 20081101 |
| Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. | Cancer chemotherapy and pharmacology 20081101 |
| Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation. | Cancer chemotherapy and pharmacology 20081101 |
| Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. | Pharmaceutical research 20081101 |
| Chemotherapy for recurrent cervical cancer. | Cancer treatment reviews 20081101 |
| Retinoblastoma: what is new in 2007-2008. | Current opinion in ophthalmology 20081101 |
| Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). | Expert opinion on investigational drugs 20081101 |
| Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. | Japanese journal of clinical oncology 20081101 |
| Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data. | Xenobiotica; the fate of foreign compounds in biological systems 20081101 |
| [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081101 |
| Future research directions for the treatment of AML. | Clinical advances in hematology & oncology : H&O 20081101 |
| Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy. | British journal of cancer 20081021 |
| Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents. | Bioorganic & medicinal chemistry 20081015 |
| Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. | Pharmaceutical research 20081001 |
| Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. | Gynecologic oncology 20081001 |
| Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). | Biochemical pharmacology 20081001 |
| Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. | Cell cycle (Georgetown, Tex.) 20081001 |
| Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination. | The British journal of radiology 20081001 |
| Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001 |
| Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. | Cancer research 20081001 |
| A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. | American journal of clinical oncology 20081001 |
| A genomic approach to identify molecular pathways associated with chemotherapy resistance. | Molecular cancer therapeutics 20081001 |
| Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. | Molecular cancer therapeutics 20081001 |
| [Down-regulation of TopI by RNA interference reduces the drug-sensitivity of small cell lung cancer cell lines to topotecan]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20081001 |
| Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. | Talanta 20080915 |
| 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents. | Bioorganic & medicinal chemistry 20080915 |
| Speeding up the evaluation of new agents in cancer. | Journal of the National Cancer Institute 20080903 |
| Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? | British journal of cancer 20080902 |
| Chemotherapy for recurrent and metastatic cervical cancer. | Gynecologic oncology 20080901 |
| Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. | Gynecologic oncology 20080901 |
| Novel chemotherapy approaches in chemoradiation protocols. | Gynecologic oncology 20080901 |
| Trilateral retinoblastoma with pituitary-hypothalamic dysfunction. | Ophthalmic genetics 20080901 |
| Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation. | Onkologie 20080901 |
| AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. | Molecular cancer therapeutics 20080901 |
| Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. | Archives of otolaryngology--head & neck surgery 20080901 |
| Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080901 |
| The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells. | Interdisciplinary toxicology 20080901 |
| Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. | Cancer chemotherapy and pharmacology 20080801 |
| The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma. | Leukemia 20080801 |
| Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. | Molecular pharmacology 20080801 |
| Topotecan treatment and its toxic effects on hematologic parameters and trace elements. | Biological trace element research 20080801 |
| Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma. | Cancer 20080801 |
| Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. | Gynecologic oncology 20080801 |
| Concomitant and neoadjuvant chemotherapy for cervical cancer. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20080801 |
| Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801 |
| Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy. | Nuclear medicine and biology 20080801 |
| [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]. | Yao xue xue bao = Acta pharmaceutica Sinica 20080801 |
| A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. | The Journal of biological chemistry 20080725 |
| Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring. | Bioorganic & medicinal chemistry letters 20080715 |
| EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. | British journal of cancer 20080708 |
| Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. | Cancer chemotherapy and pharmacology 20080701 |
| Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. | Pediatric blood & cancer 20080701 |
| Intrathecal chemotherapy delivered by a lumbar-thecal catheter in metastatic medulloblastoma: a case illustration. | Acta neurochirurgica 20080701 |
| Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080701 |
| Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. | Molecular cancer therapeutics 20080701 |
| Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. | Molecular cancer therapeutics 20080701 |
| Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. | Investigational new drugs 20080601 |
| BCRP/ABCG2 in the placenta: expression, function and regulation. | Pharmaceutical research 20080601 |
| ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin. | Molecular pharmacology 20080601 |
| Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. | Gynecologic oncology 20080601 |
| Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20080601 |
| Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling. | Mathematical biosciences 20080601 |
| Prolonged survival with continuous infusion topotecan: a report of 2 cases. | Journal of pediatric hematology/oncology 20080601 |
| ISG15 as a novel tumor biomarker for drug sensitivity. | Molecular cancer therapeutics 20080601 |
| The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line. | Cancer investigation 20080601 |
| [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1]. | Yao xue xue bao = Acta pharmaceutica Sinica 20080601 |
| Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. | British journal of cancer 20080520 |
| Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. | British journal of cancer 20080506 |
| Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. | Lung cancer (Amsterdam, Netherlands) 20080501 |
| Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. | Cancer 20080501 |
| Listen to their answers! Response behaviour in the measurement of physical and role functioning. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20080501 |
| E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation. | Bioorganic & medicinal chemistry letters 20080501 |
| Synthesis and cytotoxic activity of new 9-substituted camptothecins. | Bioorganic & medicinal chemistry letters 20080501 |
| Topoisomerase I inhibitors for the treatment of brain tumors. | Expert review of anticancer therapy 20080501 |
| Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. | Expert review of anticancer therapy 20080501 |
| A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. | Clinical lung cancer 20080501 |
| Topotecan for ovarian cancer. | The Cochrane database of systematic reviews 20080416 |
| The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. | International journal of pharmaceutics 20080402 |
| Symptom burden after autologous stem cell transplantation for multiple myeloma. | Cancer 20080401 |
| Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. | Current medical research and opinion 20080401 |
| A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. | Neuro-oncology 20080401 |
| Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20080401 |
| Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. | Cancer biology & therapy 20080401 |
| Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. | Leukemia & lymphoma 20080401 |
| Freeze drying of double emulsions to prepare topotecan-entrapping liposomes featuring controlled release. | Drug development and industrial pharmacy 20080401 |
| Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. | Anti-cancer drugs 20080401 |
| Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. | Statistics in medicine 20080330 |
| Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. | Biochemical pharmacology 20080315 |
| Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. | British journal of cancer 20080311 |
| Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. | Pediatric blood & cancer 20080301 |
| Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20080301 |
| Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. | Molecular pharmacology 20080301 |
| Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. | Gynecologic oncology 20080301 |
| Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. | Molecular cancer therapeutics 20080301 |
| [Therapeutic and adverse effects of topotecan combined with cisplatin for treatment of advanced squamous cell lung cancer and head and neck cancer]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080301 |
| Management of recurrent small cell lung cancer. | Journal of the National Comprehensive Cancer Network : JNCCN 20080301 |
| Tumor targeting using liposomal antineoplastic drugs. | International journal of nanomedicine 20080301 |
| FLIP as an anti-cancer therapeutic target. | Yonsei medical journal 20080227 |
| A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis. | British journal of cancer 20080226 |
| Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors. | Bioorganic & medicinal chemistry letters 20080215 |
| Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. | Cancer research 20080215 |
| Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. | Cancer chemotherapy and pharmacology 20080201 |
| Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. | Molecular pharmacology 20080201 |
| A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan. | Computer methods and programs in biomedicine 20080201 |
| Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain. | Oncology reports 20080201 |
| New homocamptothecins: synthesis, antitumor activity, and molecular modeling. | Bioorganic & medicinal chemistry 20080201 |
| Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma. | Investigative ophthalmology & visual science 20080201 |
| [Chemotherapy for brain tumors in adult patients]. | Der Nervenarzt 20080201 |
| Small-cell lung cancer, getting smaller but still difficult to treat. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080201 |
| Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). | Therapeutics and clinical risk management 20080201 |
| A review of topotecan in combination chemotherapy for advanced cervical cancer. | Therapeutics and clinical risk management 20080201 |
| [New strategies in pediatric ophthalmic oncology]. | Revue medicale suisse 20080116 |
| A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. | Cancer 20080115 |
| Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure. | Pediatric blood & cancer 20080101 |
| A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101 |
| Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. | Journal of neuro-oncology 20080101 |
| Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101 |
| Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101 |
| Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. | Journal of neuro-oncology 20080101 |
| A Phase I trial of weekly docetaxel and topotecan for solid tumors. | Acta oncologica (Stockholm, Sweden) 20080101 |
| Weekly topotecan for recurrent platinum resistant ovarian cancer. | Gynecologic oncology 20080101 |
| Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies. | The Journal of pharmacology and experimental therapeutics 20080101 |
| A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. | Acta oncologica (Stockholm, Sweden) 20080101 |
| Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model. | Gynecologic oncology 20080101 |
| Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents. | The Journal of pharmacy and pharmacology 20080101 |
| Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan. | International journal of oncology 20080101 |
| Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080101 |
| From plasma membrane to cytoskeleton: a novel function for semaphorin 6A. | Molecular cancer therapeutics 20080101 |
| Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. | Drug development and industrial pharmacy 20080101 |
| Binding of topotecan to a nicked DNA oligomer in solution. | Chemistry (Weinheim an der Bergstrasse, Germany) 20080101 |
| DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. | Molecular cancer 20080101 |
| Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. | PLoS medicine 20080101 |
| Chemotherapy for advanced, recurrent, and metastatic cervical cancer. | Journal of the National Comprehensive Cancer Network : JNCCN 20080101 |
| Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. | BMC genomics 20080101 |
| Prostaglandin E2 metabolism in rat brain: Role of the blood-brain interfaces. | Cerebrospinal fluid research 20080101 |
| A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101 |
| First-line randomized trials: revisiting the Ptolemaic universe. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101 |
| Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer. | Medical oncology (Northwood, London, England) 20080101 |
| Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. | BMC health services research 20080101 |
| [Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. | Gynakologisch-geburtshilfliche Rundschau 20080101 |
| Design, synthesis and development of novel camptothecin drugs. | Current pharmaceutical design 20080101 |
| Current status of clinical trials for small cell lung cancer. | Reviews on recent clinical trials 20080101 |
| PPARgamma in Neuroblastoma. | PPAR research 20080101 |
| FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate. | World journal of surgical oncology 20080101 |
| Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania major. | BMC microbiology 20080101 |
| Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. | PloS one 20080101 |
| Cell killing and resistance in pre-operative breast cancer chemotherapy. | BMC cancer 20080101 |
| Cervical lymphadenopathy - an unusual presentation of carcinoma of the cervix: a case report. | Journal of medical case reports 20080101 |
| Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. | BMC gastroenterology 20080101 |
| Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. | Journal of translational medicine 20080101 |
| EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. | BMC cancer 20080101 |
| Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. | BMC cancer 20080101 |
| Neuropsychological testing and biomarkers in the management of brain metastases. | Radiation oncology (London, England) 20080101 |
| Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. | World journal of surgical oncology 20080101 |
| Small-cell lung cancer: an unusual therapeutic approach with more than 10-year overall survival. Case report and review of the literature. | Tumori 20080101 |
| Intestinal permeability and toxicity of second-line therapeutic agents in ovarian cancer. | Tumori 20080101 |
| Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. | BMC cancer 20080101 |
| Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. | BMC cancer 20080101 |
| Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. | Molecular vision 20080101 |
| Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin. | Drug design, development and therapy 20080101 |
| Topotecan in the treatment of relapsed small cell lung cancer. | OncoTargets and therapy 20080101 |
| A review on plant-derived natural products and their analogs with anti-tumor activity. | Indian journal of pharmacology 20080101 |
| Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. | Cancer letters 20071218 |
| A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. | British journal of cancer 20071217 |
| [Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer]. | Orvosi hetilap 20071209 |
| Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. | British journal of cancer 20071203 |
| Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). | Journal of pharmaceutical sciences 20071201 |
| Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. | Journal of pharmacokinetics and pharmacodynamics 20071201 |
| Increased phosphorylation of caveolin-1 in the spinal cord of irradiated rats. | Journal of veterinary science 20071201 |
| Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20071201 |
| Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. | Molecular cancer therapeutics 20071201 |
| Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. | Molecular cancer therapeutics 20071201 |
| In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. | Molecular cancer therapeutics 20071201 |
| Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. | International journal of nanomedicine 20071201 |
| Topotecan: An evolving option in the treatment of relapsed small cell lung cancer. | Therapeutics and clinical risk management 20071201 |
| Palonosetron as an anti-emetic and anti-nausea agent in oncology. | Therapeutics and clinical risk management 20071201 |
| Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120 |
| R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. | British journal of cancer 20071119 |
| Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115 |
| Population pharmacokinetic analysis of topotecan in pediatric cancer patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071115 |
| TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. | The EMBO journal 20071114 |
| Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? | The EMBO journal 20071114 |
| Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. | Cancer chemotherapy and pharmacology 20071101 |
| Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. | Critical reviews in oncology/hematology 20071101 |
| Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. | Biomedical chromatography : BMC 20071101 |
| Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20071101 |
| Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer. | Current medical research and opinion 20071101 |
| The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. | British journal of pharmacology 20071101 |
| P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071101 |
| Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report. | Journal of pediatric hematology/oncology 20071101 |
| Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. | Anti-cancer agents in medicinal chemistry 20071101 |
| Integrated computational strategies for UV/vis spectra of large molecules in solution. | Chemical Society reviews 20071101 |
| The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. | British journal of cancer 20071022 |
| Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020 |
| UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway. | Oncogene 20071018 |
| First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action. | British journal of cancer 20071008 |
| The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa. | Oncology reports 20071001 |
| Chemotherapy for recurrent cervical cancer. | Gynecologic oncology 20071001 |
| The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. | Cancer research 20071001 |
| Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. | Leukemia & lymphoma 20071001 |
| Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. | Molecular cancer therapeutics 20071001 |
| Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model. | Current oncology (Toronto, Ont.) 20071001 |
| Optimal chemotherapy treatment for women with recurrent ovarian cancer. | Current oncology (Toronto, Ont.) 20071001 |
| Recent advances with topotecan in the treatment of lung cancer. | The oncologist 20071001 |
| [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer]. | Zhonghua fu chan ke za zhi 20071001 |
| [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071001 |
| Decitabine in the treatment of myelodysplastic syndromes. | Therapeutics and clinical risk management 20071001 |
| Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. | The Journal of biological chemistry 20070914 |
| Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. | Journal of cancer research and clinical oncology 20070901 |
| Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. | Journal of cancer research and clinical oncology 20070901 |
| Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity. | Toxicology in vitro : an international journal published in association with BIBRA 20070901 |
| Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride]. | The Journal of pharmacology and experimental therapeutics 20070901 |
| Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas. | Apoptosis : an international journal on programmed cell death 20070901 |
| Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. | Oncology reports 20070901 |
| Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070901 |
| A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20070901 |
| A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901 |
| Multi-disciplinary treatment of a rare pelvic cavity ependymoma. | Yonsei medical journal 20070831 |
| Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. | Journal of molecular biology 20070824 |
| Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? | Pediatric blood & cancer 20070801 |
| Chemical radiosensitizers for use in radiotherapy. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801 |
| Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. | Molecular pharmacology 20070801 |
| UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. | Gynecologic oncology 20070801 |
| Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. | Investigative ophthalmology & visual science 20070801 |
| Camptothecin: therapeutic potential and biotechnology. | Current pharmaceutical biotechnology 20070801 |
| The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. | Molecular cancer therapeutics 20070801 |
| Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. | Current oncology (Toronto, Ont.) 20070801 |
| Current status of second-line treatment and novel therapies for small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070801 |
| Torque and dynamics of linking number relaxation in stretched supercoiled DNA. | Physical review. E, Statistical, nonlinear, and soft matter physics 20070801 |
| Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720 |
| Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. | Biochemical pharmacology 20070715 |
| Antitumour drugs impede DNA uncoiling by topoisomerase I. | Nature 20070712 |
| Management of metastatic cervical cancer: review of the literature. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070710 |
| A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors. | International journal of radiation oncology, biology, physics 20070701 |
| Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. | Lung cancer (Amsterdam, Netherlands) 20070701 |
| A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20070701 |
| Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. | Critical reviews in oncology/hematology 20070701 |
| Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. | Drug metabolism and disposition: the biological fate of chemicals 20070701 |
| Treatment of retinoblastoma: current status and future perspectives. | Current treatment options in neurology 20070701 |
| Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070701 |
| Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070701 |
| Update in the management of ovarian and cervical carcinoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20070701 |
| Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan. | Die Pharmazie 20070701 |
| Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives. | Bioorganic & medicinal chemistry 20070615 |
| Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. | Cancer chemotherapy and pharmacology 20070601 |
| Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. | Cancer chemotherapy and pharmacology 20070601 |
| Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2. | The Journal of pharmacology and experimental therapeutics 20070601 |
| A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. | Gynecologic oncology 20070601 |
| A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070601 |
| Topotecan for the treatment of small-cell lung cancer. | Expert review of anticancer therapy 20070601 |
| Gam1-associated alterations of drug responsiveness through activation of apoptosis. | Molecular cancer therapeutics 20070601 |
| Canadian recommendations for the treatment of glioblastoma multiforme. | Current oncology (Toronto, Ont.) 20070601 |
| Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. | The Yale journal of biology and medicine 20070601 |
| Cetuximab in the management of colorectal cancer. | Biologics : targets & therapy 20070601 |
| Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070520 |
| A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. | British journal of cancer 20070507 |
| Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. | Pediatric surgery international 20070501 |
| The incidence and impact of thrombocytopenia in myelodysplastic syndromes. | Cancer 20070501 |
| The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). | British journal of pharmacology 20070501 |
| Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. | Oncology reports 20070501 |
| [A randomized study comparing topotecan plus cisplatin versus etoposide plus carboplatin for previously untreated small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20070420 |
| Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. | Cancer 20070415 |
| Hypoxia suppresses glutamate transport in astrocytes. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20070411 |
| High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. | Pediatric blood & cancer 20070401 |
| Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. | Gynecologic oncology 20070401 |
| Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression. | Molecular therapy : the journal of the American Society of Gene Therapy 20070401 |
| Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070401 |
| Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. | European journal of cancer (Oxford, England : 1990) 20070401 |
| ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. | Anti-cancer drugs 20070401 |
| Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401 |
| [TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis]. | Medecine sciences : M/S 20070401 |
| Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. | Cancer biology & therapy 20070401 |
| Temozolomide as salvage treatment in primary brain lymphomas. | British journal of cancer 20070326 |
| Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. | International journal of radiation oncology, biology, physics 20070315 |
| A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. | British journal of cancer 20070312 |
| Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. | British journal of cancer 20070312 |
| A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. | Gynecologic oncology 20070301 |
| Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. | International journal of cancer 20070301 |
| Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. | Leukemia 20070301 |
| Treatment options for relapsed small-cell lung cancer. | Anti-cancer drugs 20070301 |
| Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake. | International journal of oncology 20070301 |
| ABCG2: determining its relevance in clinical drug resistance. | Cancer metastasis reviews 20070301 |
| Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. | Molecular cancer therapeutics 20070301 |
| Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20070301 |
| Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. | Yonsei medical journal 20070227 |
| Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070215 |
| A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. | Gynecologic oncology 20070201 |
| Effects of topotecan treatment on nasal, buccal, and lingual mucosa in the rabbit: light and transmission electron microscopic evaluation. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20070201 |
| Topotecan in the management of cervical cancer. | Expert opinion on pharmacotherapy 20070201 |
| Chemotherapy resistance and oncogene expression in non-small cell lung cancer. | The Journal of thoracic and cardiovascular surgery 20070201 |
| Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. | Journal of pediatric hematology/oncology 20070201 |
| Structures, biogenesis, and biological activities of pyrano[4,3-c]isochromen-4-one derivatives from the Fungus Phellinus igniarius. | Journal of natural products 20070201 |
| New Agents in Clinical Oncology. 24 November 2006, London, UK. | IDrugs : the investigational drugs journal 20070201 |
| New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. | The oncologist 20070201 |
| Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient. | Gan to kagaku ryoho. Cancer & chemotherapy 20070201 |
| Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070201 |
| Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. | British journal of cancer 20070115 |
| Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. | Neuro-oncology 20070101 |
| The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. | Molecular pharmacology 20070101 |
| Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070101 |
| Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines. | Pharmacological research 20070101 |
| Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. | Expert opinion on drug safety 20070101 |
| Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. | Journal of pediatric surgery 20070101 |
| Functional genomics analysis of low concentration of ethanol in human hepatocellular carcinoma (HepG2) cells. Role of genes involved in transcriptional and translational processes. | International journal of medical sciences 20070101 |
| Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. | The oncologist 20070101 |
| Clinical radionuclide therapy dosimetry: the quest for the 'Holy Gray'. | European journal of nuclear medicine and molecular imaging 20070101 |
| Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Topotecan more effective than supportive care. | The Lancet. Oncology 20070101 |
| A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. | Breast cancer research : BCR 20070101 |
| relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. | Theoretical biology & medical modelling 20070101 |
| Cyclophosphamide 'metronomic' chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. | BMC cancer 20070101 |
| Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. | PloS one 20070101 |
| Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| [Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys]. | Therapie 20070101 |
| Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. | BMC cancer 20070101 |
| ATM activation accompanies histone H2AX phosphorylation in A549 cells upon exposure to tobacco smoke. | BMC cell biology 20070101 |
| Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis. | Anticancer research 20070101 |
| External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. | BMC cancer 20070101 |
| Numerical modelling of label-structured cell population growth using CFSE distribution data. | Theoretical biology & medical modelling 20070101 |
| STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. | Anticancer research 20070101 |
| Radiotherapeutic alternatives for previously irradiated recurrent gliomas. | BMC cancer 20070101 |
| Automated recognition of cell phenotypes in histology images based on membrane- and nuclei-targeting biomarkers. | BMC medical imaging 20070101 |
| Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases. | Medical oncology (Northwood, London, England) 20070101 |
| [Small cell lung cancer--state of the art and future perspectives]. | Revista portuguesa de pneumologia 20070101 |
| Modern management of small-cell lung cancer. | Drugs 20070101 |
| Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. | BMC pharmacology 20070101 |
| A novel camptothecin analog with enhanced antitumor activity. | Anticancer research 20070101 |
| Topotecan in cervical cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Bone metastasis from ovarian cancer. | Journal of cancer research and therapeutics 20070101 |
| Computational analysis of biological functions and pathways collectively targeted by co-expressed microRNAs in cancer. | BMC bioinformatics 20070101 |
| Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS). | Klinische Padiatrie 20070101 |
| Optimal management strategies for rhabdomyosarcoma in children. | Paediatric drugs 20070101 |
| Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. | BMC cancer 20070101 |
| [Small cell lung cancer]. | Wiener klinische Wochenschrift 20070101 |
| Breast tumour angiogenesis. | Breast cancer research : BCR 20070101 |
| Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia. | Anticancer research 20070101 |
| Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20070101 |
| Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. | Oncology 20070101 |
| [Relationship between chemosensitivity in vitro and the expression of GRP78 in non-small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20061220 |
| ABCG2 expression, function, and promoter methylation in human multiple myeloma. | Blood 20061201 |
| A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. | Journal of pharmaceutical sciences 20061201 |
| Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha. | Bioorganic & medicinal chemistry letters 20061201 |
| Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20061201 |
| Gamma-ray irradiation stimulates the expression of caveolin-1 and GFAP in rat spinal cord: a study of immunoblot and immunohistochemistry. | Journal of veterinary science 20061201 |
| Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. | Biological chemistry 20061201 |
| Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061201 |
| Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. | Cancer research 20061201 |
| Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF? | Xenobiotica; the fate of foreign compounds in biological systems 20061201 |
| [Routine chemotherapeutic drug treatment effectiveness predictive molecules and chemotherapeutic drug selection]. | Ai zheng = Aizheng = Chinese journal of cancer 20061201 |
| Cucurbitane triterpenes from the fruiting bodies and cultivated mycelia of Leucopaxillus gentianeus. | Journal of natural products 20061201 |
| A review of topoisomerase inhibition in lung cancer. | Cancer biology & therapy 20061201 |
| New methods for direct delivery of chemotherapy for treating brain tumors. | The Yale journal of biology and medicine 20061201 |
| Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. | Cancer research 20061115 |
| Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. | Pediatric blood & cancer 20061101 |
| Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. | Pediatric blood & cancer 20061101 |
| BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. | Cancer chemotherapy and pharmacology 20061101 |
| Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. | Gynecologic oncology 20061101 |
| Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. | Gynecologic oncology 20061101 |
| Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. | Gynecologic oncology 20061101 |
| Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20061101 |
| Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. | Molecular and cellular biology 20061101 |
| Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20061101 |
| Intrathecal topotecan in adult patients with neoplastic meningitis. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061101 |
| Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate. | Anti-cancer drugs 20061101 |
| A nitrogen-containing 3-alkyl-1,4-benzoquinone and a gomphilactone derivative from Embelia ribes. | Journal of natural products 20061101 |
| Cerebral and parotid metachronous metastases from an ovarian carcinoma. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061101 |
| [Small cell lung cancer (CPC). Second line treatment]. | Revue des maladies respiratoires 20061101 |
| Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101 |
| Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101 |
| Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101 |
| [Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061101 |
| Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. | British journal of cancer 20061023 |
| Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. | British journal of cancer 20061009 |
| Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial. | Cancer chemotherapy and pharmacology 20061001 |
| CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. | Gynecologic oncology 20061001 |
| Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. | Cancer 20061001 |
| Potential use of the adenosine triphosphate cell viability assay in endometrial cancer. | Journal of the Society for Gynecologic Investigation 20061001 |
| Topoisomerase I inhibitors: camptothecins and beyond. | Nature reviews. Cancer 20061001 |
| Antitumor activity of nifurtimox observed in a patient with neuroblastoma. | Journal of pediatric hematology/oncology 20061001 |
| New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. | Future oncology (London, England) 20061001 |
| Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. | Molecular cancer therapeutics 20061001 |
| Papillary serous carcinoma of peritoneum: presentation of 2 cases. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001 |
| Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. | Oncology (Williston Park, N.Y.) 20061001 |
| Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma. | Canadian journal of physiology and pharmacology 20061001 |
| Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060915 |
| A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. | British journal of cancer 20060904 |
| Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. | Cancer chemotherapy and pharmacology 20060901 |
| Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. | The Journal of pharmacology and experimental therapeutics 20060901 |
| Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies. | Investigational new drugs 20060901 |
| Chemotherapy for recurrent cervical carcinoma. | Current opinion in oncology 20060901 |
| Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status. | Clinical lung cancer 20060901 |
| Pegylated liposomal doxorubicin in ovarian cancer. | International journal of nanomedicine 20060901 |
| Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. | International journal of nanomedicine 20060901 |
| [Treatment of epithelial ovarian cancer]. | Orvosi hetilap 20060827 |
| Synthesis and cytotoxic activity of polyamine analogues of camptothecin. | Journal of medicinal chemistry 20060824 |
| Copper-topotecan complexation mediates drug accumulation into liposomes. | Journal of controlled release : official journal of the Controlled Release Society 20060810 |
| In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. | British journal of cancer 20060807 |
| Is it time for some new approaches for treating advanced ovarian cancer? | Journal of the National Cancer Institute 20060802 |
| Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. | Journal of the National Cancer Institute 20060802 |
| Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. | Cancer chemotherapy and pharmacology 20060801 |
| Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. | Gynecologic oncology 20060801 |
| Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine. | Cancer biology & therapy 20060801 |
| A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20060801 |
| Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. | Molecular cancer therapeutics 20060801 |
| Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. | Leukemia & lymphoma 20060801 |
| Important differences between topoisomerase-I and -II targeting agents. | Cancer biology & therapy 20060801 |
| Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management. | Danish medical bulletin 20060801 |
| Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720 |
| HIF-1 and tumour radiosensitivity. | British journal of cancer 20060703 |
| Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. | Histology and histopathology 20060701 |
| Prospective trial on topotecan salvage therapy in primary CNS lymphoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20060701 |
| Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. | Neuro-oncology 20060701 |
| Convection-enhanced delivery in the treatment of malignant glioma. | Neurological research 20060701 |
| Second-line treatment of small-cell lung cancer. | Current oncology reports 20060701 |
| Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620 |
| Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620 |
| Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. | British journal of cancer 20060619 |
| Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study. | Cancer chemotherapy and pharmacology 20060601 |
| A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. | Cancer chemotherapy and pharmacology 20060601 |
| Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. | The European respiratory journal 20060601 |
| Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice. | European journal of clinical investigation 20060601 |
| Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. | Pharmacogenetics and genomics 20060601 |
| Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? | Expert opinion on pharmacotherapy 20060601 |
| American Association for Cancer Research--97th annual meeting. | IDrugs : the investigational drugs journal 20060601 |
| Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. | American journal of clinical oncology 20060601 |
| Mono-, Bi-, and triphenanthrenes from the tubers of Cremastra appendiculata. | Journal of natural products 20060601 |
| Promoting best gynecologic oncology practice: a role for the Society of Gynecologic Oncologists of Canada. | Current oncology (Toronto, Ont.) 20060601 |
| Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. | Journal of controlled release : official journal of the Controlled Release Society 20060530 |
| A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. | Journal of controlled release : official journal of the Controlled Release Society 20060515 |
| Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. | British journal of cancer 20060508 |
| 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. | Bioorganic & medicinal chemistry 20060501 |
| Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501 |
| Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501 |
| Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. | Cancer research 20060501 |
| Ewing's sarcoma family of tumors: current management. | The oncologist 20060501 |
| Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan. | The oncologist 20060501 |
| Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. | Clinical lung cancer 20060501 |
| A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature. | Annals of oncology : official journal of the European Society for Medical Oncology 20060501 |
| Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results. | Annals of oncology : official journal of the European Society for Medical Oncology 20060501 |
| Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. | Cancer chemotherapy and pharmacology 20060401 |
| Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. | International journal of cancer 20060401 |
| Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. | Gynecologic oncology 20060401 |
| Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. | Blood 20060401 |
| Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. | Journal of neuro-oncology 20060401 |
| A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. | Journal of neuro-oncology 20060401 |
| Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). | Drug metabolism and disposition: the biological fate of chemicals 20060401 |
| Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. | Neuro-oncology 20060401 |
| Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. | Bone marrow transplantation 20060401 |
| Chemotherapy in the management of cervical carcinoma. | Clinical advances in hematology & oncology : H&O 20060401 |
| A study of variable hydration states in topotecan hydrochloride. | Journal of pharmaceutical and biomedical analysis 20060318 |
| Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. | Biochemical pharmacology 20060314 |
| Experimental designs for phase I and phase I/II dose-finding studies. | British journal of cancer 20060313 |
| Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. | Cancer letters 20060308 |
| Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. | Gynecologic oncology 20060301 |
| Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. | Leukemia & lymphoma 20060301 |
| Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. | Leukemia & lymphoma 20060301 |
| Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. | Cancer 20060301 |
| Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. | Cancer science 20060301 |
| Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20060301 |
| [Medical treatment of metastatic or recurrent cancer of the cervix]. | Bulletin du cancer 20060301 |
| [Inhibition effect of topotecan on human myelodysplastic syndrome cells in vitro and in vivo]. | Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060301 |
| Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301 |
| Comparison of efficacy and toxicity profile between intraperitoneal and intravenous topotecan in human ovarian cancer xenografts. | Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20060218 |
| Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis. | European journal of pharmacology 20060217 |
| Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. | Gynecologic oncology 20060201 |
| Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. | Molecular pharmacology 20060201 |
| DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. | The Journal of pharmacology and experimental therapeutics 20060201 |
| Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. | Annals of oncology : official journal of the European Society for Medical Oncology 20060201 |
| Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. | Bone marrow transplantation 20060201 |
| ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis. | Cell proliferation 20060201 |
| Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. | The Annals of thoracic surgery 20060201 |
| Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line. | Biochemistry and cell biology = Biochimie et biologie cellulaire 20060201 |
| Optimizing therapy in previously treated non-small cell lung cancer. | Seminars in oncology 20060201 |
| The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome. | Journal of Korean medical science 20060201 |
| A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. | Molecular cancer therapeutics 20060201 |
| Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/macrophage (CFU-GM) assay. | Die Pharmazie 20060201 |
| [Is small cell lung cancer an orphan disease?]. | Revue de pneumologie clinique 20060201 |
| [From ASCO and WCLC 2005 to clinical practice: 'conventional' treatments]. | Revue de pneumologie clinique 20060201 |
| Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. | British journal of cancer 20060116 |
| A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. | British journal of cancer 20060116 |
| SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. | British journal of cancer 20060116 |
| SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. | British journal of cancer 20060116 |
| Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. | Cancer chemotherapy and pharmacology 20060101 |
| Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). | Cancer chemotherapy and pharmacology 20060101 |
| A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. | Gynecologic oncology 20060101 |
| Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. | Cancer chemotherapy and pharmacology 20060101 |
| Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. | Gynecologic oncology 20060101 |
| Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts. | Journal of neuro-oncology 20060101 |
| Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. | Trends in pharmacological sciences 20060101 |
| Second- and third-line treatments in non-small cell lung cancer. | Current treatment options in oncology 20060101 |
| Rubitecan. | Expert opinion on investigational drugs 20060101 |
| Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101 |
| Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. | BMC cancer 20060101 |
| Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. | Molecular cancer therapeutics 20060101 |
| Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Topotecan is a substrate for multidrug resistance associated protein 4. | Current drug metabolism 20060101 |
| Early patterns of verbal memory impairment in children treated for medulloblastoma. | Neuropsychology 20060101 |
| Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine. | BMC cell biology 20060101 |
| Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. | Drug safety 20060101 |
| Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer. | Neoplasia (New York, N.Y.) 20060101 |
| Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. | BMC cancer 20060101 |
| Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. | Journal of translational medicine 20060101 |
| Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). | BMC cancer 20060101 |
| Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. | Molecular cancer 20060101 |
| Radiosensitizers in cervical cancer. Cisplatin and beyond. | Radiation oncology (London, England) 20060101 |
| Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. | Radiation oncology (London, England) 20060101 |
| Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale). | Anticancer research 20060101 |
| Signatures of human regulatory T cells: an encounter with old friends and new players. | Genome biology 20060101 |
| Review camptothecin: current perspectives. | Current medicinal chemistry 20060101 |
| Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. | BMC cancer 20060101 |
| Pharmacokinetic considerations in the treatment of CNS tumours. | Clinical pharmacokinetics 20060101 |
| New agents for intrathecal administration. | Cancer investigation 20060101 |
| Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. | Cancer cell international 20060101 |
| New molecular mechanisms of action of camptothecin-type drugs. | Anticancer research 20060101 |
| Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. | BMC cancer 20060101 |
| Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial. | Acta haematologica 20060101 |
| Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. | Molecular cancer 20060101 |
| A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. | Clinical drug investigation 20060101 |
| Topotecan as a second-line therapy in patients with ovarian and primary peritoneal cancer: initial response and long-term follow-up. | European journal of gynaecological oncology 20060101 |
| Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20060101 |
| Drug approved for late-stage cervical cancer. | FDA consumer 20060101 |
| Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution. | Sarcoma 20060101 |
| Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells. | Oncology 20060101 |
| Brain metastasis--evidence based management. | Journal of cancer research and therapeutics 20060101 |
| Colorectal cancer: from epidemiology to current treatment. | The Libyan journal of medicine 20060101 |
| The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity. | Colloids and surfaces. B, Biointerfaces 20051220 |
| Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents. | Bioorganic & medicinal chemistry 20051215 |
| Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. | Cancer 20051215 |
| A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. | Gynecologic oncology 20051201 |
| Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. | Oncology reports 20051201 |
| The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051201 |
| Ayurveda and traditional Chinese medicine: a comparative overview. | Evidence-based complementary and alternative medicine : eCAM 20051201 |
| Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. | Haematologica 20051201 |
| Phase I study of docetaxel and topotecan in patients with advanced malignancies. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20051201 |
| Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial. | British journal of cancer 20051114 |
| New hints on the Ph-driven tautomeric equilibria of the topotecan anticancer drug in aqueous solutions from an integrated spectroscopic and quantum-mechanical approach. | Journal of the American Chemical Society 20051109 |
| Augmenting tumor sensitivity to topotecan by transient hypoxia. | Cancer chemotherapy and pharmacology 20051101 |
| Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. | Annals of oncology : official journal of the European Society for Medical Oncology 20051101 |
| Plant-based anticancer molecules: a chemical and biological profile of some important leads. | Bioorganic & medicinal chemistry 20051101 |
| Human multidrug resistance associated protein 4 confers resistance to camptothecins. | Pharmaceutical research 20051101 |
| Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20051101 |
| Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. | Current oncology reports 20051101 |
| [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051101 |
| Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. | Clinical lung cancer 20051101 |
| Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. | Clinical lung cancer 20051101 |
| [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma. | Cancer letters 20051018 |
| A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. | British journal of cancer 20051017 |
| The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. | Biochemical pharmacology 20051015 |
| Topotecan combination chemotherapy in two new rodent models of retinoblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051015 |
| Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. | British journal of cancer 20051003 |
| Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). | Cancer chemotherapy and pharmacology 20051001 |
| High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. | Annals of hematology 20051001 |
| Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. | Leukemia research 20051001 |
| Hypoxia inducible factor-1: a novel target for cancer therapy. | Anti-cancer drugs 20051001 |
| Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. | Cancer research 20051001 |
| Topotecan in platinum-resistant epithelial ovarian cancer. | Chemotherapy 20051001 |
| Use of preclinical models to improve treatment of retinoblastoma. | PLoS medicine 20051001 |
| Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. | The oncologist 20051001 |
| Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. | The oncologist 20051001 |
| Topotecan: weighing in when there are many options. | The oncologist 20051001 |
| Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. | The oncologist 20051001 |
| In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan. | The Journal of pharmacy and pharmacology 20051001 |
| Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. | Clinical breast cancer 20051001 |
| Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives. | Journal of pharmaceutical and biomedical analysis 20050915 |
| One- and two-stage designs for stratified phase II clinical trials. | Statistics in medicine 20050915 |
| Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050915 |
| Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. | Biochemical pharmacology 20050901 |
| Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. | Gynecologic oncology 20050901 |
| Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. | Journal of cancer research and clinical oncology 20050901 |
| Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. | Clinical lung cancer 20050901 |
| Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. | Oncology (Williston Park, N.Y.) 20050901 |
| Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy. | Current drug discovery technologies 20050901 |
| Plants as a source of anti-cancer agents. | Journal of ethnopharmacology 20050822 |
| [Topotecan in combination with cisplatin in the treatment of recurrent small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20050820 |
| Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050815 |
| New drugs target hypoxia response in tumors. | Journal of the National Cancer Institute 20050803 |
| Single nucleotide polymorphisms modify the transporter activity of ABCG2. | Cancer chemotherapy and pharmacology 20050801 |
| Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. | Cancer chemotherapy and pharmacology 20050801 |
| Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. | Drug metabolism and disposition: the biological fate of chemicals 20050801 |
| Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. | Molecular pharmacology 20050801 |
| Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. | Gynecologic oncology 20050801 |
| Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. | Gynecologic oncology 20050801 |
| A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20050801 |
| Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report. | Anti-cancer drugs 20050801 |
| Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. | Cancer research 20050801 |
| Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. | Cancer science 20050801 |
| Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050720 |
| Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050720 |
| A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. | Cancer research 20050715 |
| Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. | British journal of cancer 20050711 |
| A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. | British journal of cancer 20050711 |
| Chemotherapy dosing in the setting of liver dysfunction. | Oncology (Williston Park, N.Y.) 20050701 |
| Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620 |
| Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. | Drug metabolism and disposition: the biological fate of chemicals 20050601 |
| Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. | Lung cancer (Amsterdam, Netherlands) 20050601 |
| Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). | Lung cancer (Amsterdam, Netherlands) 20050601 |
| Effect of ABCG2 genotype on the oral bioavailability of topotecan. | Cancer biology & therapy 20050601 |
| DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. | Molecular and cellular biology 20050601 |
| Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. | Cancer research 20050601 |
| Management of leptomeningeal malignancy. | Expert opinion on pharmacotherapy 20050601 |
| High dose chemotherapy and transplantation of hematopoietic progenitors from murine D3 embryonic stem cells. | Journal of chemotherapy (Florence, Italy) 20050601 |
| Advances in the management of epithelial ovarian cancer. | The Journal of reproductive medicine 20050601 |
| Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin. | British journal of cancer 20050509 |
| Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. | Molecular pharmacology 20050501 |
| The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. | The Journal of surgical research 20050501 |
| Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity. | International journal of radiation oncology, biology, physics 20050501 |
| Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. | Chemotherapy 20050501 |
| Cell cycle effects of topotecan alone and in combination with irradiation. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20050501 |
| Emerging drugs for ovarian cancer. | Expert opinion on emerging drugs 20050501 |
| In vitro and in vivo studies of different liposomes containing topotecan. | Archives of pharmacal research 20050501 |
| Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050425 |
| HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. | British journal of cancer 20050425 |
| Synthesis and antitumor activity of 7-ethyl-9-alkyl derivatives of camptothecin. | Bioorganic & medicinal chemistry letters 20050415 |
| Serum cystatin C is a better marker of topotecan clearance than serum creatinine. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050415 |
| Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. | Journal of medicinal chemistry 20050407 |
| Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. | Cancer 20050401 |
| CA125 Nadir values as a prognostic factor in epithelial ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050401 |
| Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. | Clinical neurology and neurosurgery 20050401 |
| [Effect of bone marrow stromal cells on the apoptotic sensitivity of HL-60 and HL-60/VCR cells]. | Zhongguo shi yan xue ye xue za zhi 20050401 |
| Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. | Cancer biotherapy & radiopharmaceuticals 20050401 |
| Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. | British journal of cancer 20050328 |
| Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320 |
| Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. | Cancer letters 20050318 |
| Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. | Drug metabolism and disposition: the biological fate of chemicals 20050301 |
| A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20050301 |
| Expression of p53 and p21 in primary glioblastomas. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20050301 |
| Alternative administration of camptothecin analogues. | Expert opinion on drug delivery 20050301 |
| Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. | British journal of cancer 20050227 |
| High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225 |
| In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. | International journal of cancer 20050220 |
| Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. | Cancer research 20050215 |
| MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050215 |
| 5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. | Journal of medicinal chemistry 20050210 |
| Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. | Gynecologic oncology 20050201 |
| The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. | Nature medicine 20050201 |
| Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. | Cancer research 20050201 |
| A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. | Journal of neuro-oncology 20050201 |
| Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. | Neoplasia (New York, N.Y.) 20050201 |
| A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. | British journal of cancer 20050117 |
| Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. | Cancer research 20050115 |
| Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells. | Advanced drug delivery reviews 20050102 |
| Panniculitis induced by a chemotherapy regimen consisting of topotecan and cyclophosphamide. | Pediatric blood & cancer 20050101 |
| Role of pegylated liposomal doxorubicin in ovarian cancer. | Gynecologic oncology 20050101 |
| Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to in situ detect active acetylcholinesterase (AChE) induced during apoptosis. | Cell cycle (Georgetown, Tex.) 20050101 |
| Efficacy of topotecan treatment on antioxidant enzymes and TBA-RS levels in submandibular glands of rabbits: an experimental study. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20050101 |
| Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. | Clinical pharmacokinetics 20050101 |
| Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20050101 |
| Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. | Expert opinion on pharmacotherapy 20050101 |
| Toxicity of the topoisomerase I inhibitors. | Expert opinion on drug safety 20050101 |
| In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. | Journal of neuro-oncology 20050101 |
| High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. | Journal of neuro-oncology 20050101 |
| Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. | American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101 |
| Future options for first-line therapy of advanced ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101 |
| The effects of topotecan on lipid peroxidation and antioxidant enzyme levels in rabbit liver tissue. | Redox report : communications in free radical research 20050101 |
| Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101 |
| Current concepts of treatment strategies in advanced or recurrent ovarian cancer. | Oncology 20050101 |
| Cancer cell adaptation to chemotherapy. | BMC cancer 20050101 |
| Brain metastases in breast cancer--an in vitro study to evaluate new systemic chemotherapeutic options. | Anticancer research 20050101 |
| Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. | Anticancer research 20050101 |
| Recent developments in the clinical activity of topoisomerase-1 inhibitors. | Cancer chemotherapy and biological response modifiers 20050101 |
| p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. | Oncology 20050101 |
| Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus. | Anticancer research 20050101 |
| Anthracyclines, proteasome activity and multi-drug-resistance. | BMC cancer 20050101 |
| Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients. | The Journal of oncology management : the official journal of the American College of Oncology Administrators 20050101 |
| Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. | Breast cancer research : BCR 20050101 |
| Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. | Breast cancer research : BCR 20050101 |
| Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101 |
| Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. | Cancer investigation 20050101 |
| ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. | Cancer cell international 20050101 |
| A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. | Cancer investigation 20050101 |
| Epigenetics of cervical cancer. An overview and therapeutic perspectives. | Molecular cancer 20050101 |
| The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line. | Acta biochimica Polonica 20050101 |
| First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study. | BMC cancer 20050101 |
| Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101 |
| Randomized single-agents trials in recurrent epithelial ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101 |
| Gemcitabine in patients with ovarian cancer. | Cancer treatment reviews 20050101 |
| Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. | Cancer investigation 20050101 |
| The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. | Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 20050101 |
| Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. | The Journal of biological chemistry 20041224 |
| HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. | Cancer research 20041215 |
| Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. | Best practice & research. Clinical haematology 20041201 |
| Heterogeneous cell response to topotecan in a CFSE-based proliferation test. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20041201 |
| Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. | Journal of neurochemistry 20041201 |
| Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. | Gynecologic oncology 20041201 |
| Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. | Gynecologic oncology 20041201 |
| Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041201 |
| In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468). | International journal of radiation oncology, biology, physics 20041201 |
| Mechanism-based models for topotecan-induced neutropenia. | Clinical pharmacology and therapeutics 20041201 |
| The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20041201 |
| Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. | Molecular cancer therapeutics 20041201 |
| The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. | Molecular cancer therapeutics 20041201 |
| Treatment of patients with advanced lung cancer and poor performance status. | Clinical lung cancer 20041201 |
| Liposomal anthracycline treatment for ovarian cancer. | Seminars in oncology 20041201 |
| Pharmacoeconomics of liposomal anthracycline therapy. | Seminars in oncology 20041201 |
| Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes. | Reviews in clinical and experimental hematology 20041201 |
| Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. | Bioorganic & medicinal chemistry letters 20041115 |
| Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. | British journal of cancer 20041115 |
| Recurrent ovarian cancer: how important is it to treat to disease progression? | Clinical cancer research : an official journal of the American Association for Cancer Research 20041115 |
| Multiple binding modes of the camptothecin family to DNA oligomers. | Chemistry (Weinheim an der Bergstrasse, Germany) 20041105 |
| Review of the use of topotecan in ovarian carcinoma. | Expert opinion on pharmacotherapy 20041101 |
| Recent advances in primary CNS lymphoma. | Current opinion in oncology 20041101 |
| Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer. | Journal of chemotherapy (Florence, Italy) 20041101 |
| Topotecan induced nail pigmentation. | The Journal of dermatology 20041101 |
| [Effect of palliative chemotherapy with topoisomerase inhibitor on the quality of life and survival of patients with advanced colorectal carcinoma]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20041101 |
| Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. | Journal of medicinal chemistry 20041021 |
| A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. | British journal of cancer 20041018 |
| Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. | British journal of cancer 20041018 |
| Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041015 |
| Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041015 |
| A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041015 |
| Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. | British journal of cancer 20041004 |
| Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. | Annals of hematology 20041001 |
| The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. | Critical reviews in oncology/hematology 20041001 |
| Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. | Gynecologic oncology 20041001 |
| Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. | Gynecologic oncology 20041001 |
| Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. | Gynecologic oncology 20041001 |
| Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. | Cancer research 20041001 |
| Camptothecin, over four decades of surprising findings. | Phytochemistry 20041001 |
| A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041001 |
| Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01. | Journal of experimental therapeutics & oncology 20041001 |
| Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040915 |
| No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. | British journal of cancer 20040913 |
| Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. | British journal of cancer 20040913 |
| Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. | Cancer chemotherapy and pharmacology 20040901 |
| Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. | Journal of pharmaceutical sciences 20040901 |
| Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation? | Annals of oncology : official journal of the European Society for Medical Oncology 20040901 |
| The treatment of neoplastic meningitis. | Expert opinion on pharmacotherapy 20040901 |
| Topotecan disposition in an anephric child. | Journal of pediatric hematology/oncology 20040901 |
| Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. | Journal of immunological methods 20040901 |
| Gefitinib reverses breast cancer resistance protein-mediated drug resistance. | Molecular cancer therapeutics 20040901 |
| Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. | Clinical colorectal cancer 20040901 |
| Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. | Journal of the National Comprehensive Cancer Network : JNCCN 20040901 |
| A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. | British journal of cancer 20040816 |
| Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. | British journal of cancer 20040816 |
| Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040815 |
| Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. | Cancer research 20040815 |
| Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin. | Bioorganic & medicinal chemistry letters 20040802 |
| Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). | British journal of cancer 20040802 |
| Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. | Cancer chemotherapy and pharmacology 20040801 |
| Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? | Gynecologic oncology 20040801 |
| Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. | Gynecologic oncology 20040801 |
| [Synthesis and antitumor activity of 20-O-linked camptothecin ester derivatives]. | Yao xue xue bao = Acta pharmaceutica Sinica 20040801 |
| Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. | Carcinogenesis 20040701 |
| The telomeric region is excluded from nucleosomal fragmentation during apoptosis, but the bulk nuclear chromatin is randomly degraded. | Cell death and differentiation 20040701 |
| Combined topoisomerase I inhibition for the treatment of metastatic colon cancer. | Anti-cancer drugs 20040701 |
| Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040701 |
| The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. | Gynecologic oncology 20040701 |
| Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. | Gynecologic oncology 20040701 |
| [A case of brain metastasis of small cell lung cancer improved with nogitecan hydrochloride (topotecan) after prophylactic irradiation]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040701 |
| Topotecan-induced bronchiolitis. | Southern medical journal 20040701 |
| A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. | Statistics in medicine 20040630 |
| A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. | Cancer 20040615 |
| Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. | Cancer research 20040615 |
| Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. | British journal of cancer 20040614 |
| A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. | British journal of cancer 20040614 |
| Mechanisms of camptothecin resistance by human topoisomerase I mutations. | Journal of molecular biology 20040611 |
| A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. | Mathematical biosciences 20040601 |
| A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. | Leukemia research 20040601 |
| Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. | Bone marrow transplantation 20040601 |
| 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. | International journal of radiation oncology, biology, physics 20040601 |
| Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. | American journal of clinical oncology 20040601 |
| Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. | Gynecologic oncology 20040601 |
| Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. | Gynecologic oncology 20040601 |
| Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. | Oncology (Williston Park, N.Y.) 20040601 |
| Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. | Neurology 20040525 |
| An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. | Journal of controlled release : official journal of the Controlled Release Society 20040518 |
| Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. | Cancer 20040515 |
| Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040515 |
| Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. | Gynecologic oncology 20040501 |
| Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. | European journal of cancer (Oxford, England : 1990) 20040501 |
| Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040501 |
| Phelligridins C-F: cytotoxic pyrano[4,3-c][2]benzopyran-1,6-dione and furo[3,2-c]pyran-4-one derivatives from the fungus Phellinus igniarius. | Journal of natural products 20040501 |
| Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. | Acta paediatrica (Oslo, Norway : 1992). Supplement 20040501 |
| [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I]. | Yao xue xue bao = Acta pharmaceutica Sinica 20040501 |
| Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415 |
| A window on reality? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415 |
| Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. | Cancer 20040415 |
| Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. | Cancer research 20040415 |
| Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. | Cancer research 20040415 |
| A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. | Lung cancer (Amsterdam, Netherlands) 20040401 |
| Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. | Gynecologic oncology 20040401 |
| A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. | Gynecologic oncology 20040401 |
| Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20040401 |
| Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. | Cancer research 20040401 |
| A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. | Leukemia research 20040401 |
| [Structure-activity relationship analysis]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040401 |
| Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. | Pharmaceutical research 20040401 |
| Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia. | Leukemia & lymphoma 20040401 |
| High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. | Leukemia & lymphoma 20040401 |
| Targeted therapies in myelodysplastic syndromes: ASH 2003 review. | Seminars in hematology 20040401 |
| Subcellular localization of the camptothecin analogues, topotecan and gimatecan. | Biochemical pharmacology 20040315 |
| Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20040301 |
| Comparison of the X-radiation, drug and ultraviolet-radiation responses of clones isolated from a human colorectal tumor cell line. | Radiation research 20040301 |
| Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. | Gynecologic oncology 20040301 |
| Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301 |
| Camptothecins in clinical development. | Expert opinion on investigational drugs 20040301 |
| VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040301 |
| Evolving role of topotecan in treating small-cell lung cancer. | Clinical lung cancer 20040301 |
| [The mechanism of topotecan resistance in ovarian cancer cell line]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20040301 |
| Activity of topotecan in retinoblastoma. | Ophthalmic genetics 20040301 |
| A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. | British journal of cancer 20040223 |
| N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. | British journal of cancer 20040223 |
| Mode of binding of camptothecins to double helix oligonucleotides. | Organic & biomolecular chemistry 20040221 |
| 11H-Isoquino[4,3-c]cinnolin-12-ones; novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity. | Bioorganic & medicinal chemistry 20040215 |
| Pheophorbide a is a specific probe for ABCG2 function and inhibition. | Cancer research 20040215 |
| Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. | Cancer research 20040215 |
| Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. | Cancer research 20040215 |
| Targeting topoisomerase I to inhibit hypoxia inducible factor 1. | Cell cycle (Georgetown, Tex.) 20040201 |
| Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20040201 |
| Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. | Gynecologic oncology 20040201 |
| Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040201 |
| Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040201 |
| Recurrent ovarian cancer. | Onkologie 20040201 |
| Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum. | Onkologie 20040201 |
| Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. | British journal of cancer 20040126 |
| Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? | British journal of cancer 20040126 |
| An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. | International journal of cancer 20040110 |
| Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. | Journal of the National Cancer Institute 20040107 |
| Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. | Leukemia 20040101 |
| A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. | Cancer chemotherapy and pharmacology 20040101 |
| Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. | International journal of cancer 20040101 |
| Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. | Leukemia research 20040101 |
| Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20040101 |
| Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. | The American journal of medicine 20040101 |
| A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. | Cancer biology & therapy 20040101 |
| Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| Topotecan in small cell lung cancer: first or second line? | Cancer biology & therapy 20040101 |
| In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. | Gynecologic oncology 20040101 |
| Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. | Pediatric blood & cancer 20040101 |
| Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. | Current medicinal chemistry. Anti-cancer agents 20040101 |
| Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. | The oncologist 20040101 |
| The role of topotecan in the treatment of brain metastases. | The oncologist 20040101 |
| Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. | Molecular cancer research : MCR 20040101 |
| Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. | The oncologist 20040101 |
| High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. | Journal of neuro-oncology 20040101 |
| [Ovarian cancer--therapeutic options after the failure of the first line of treatment]. | Ginekologia polska 20040101 |
| The incidence of port-site metastases in gynecologic cancers. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20040101 |
| Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). | BMC medicine 20040101 |
| Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients. | Anticancer research 20040101 |
| Inhibitory effect of genistein and daidzein on ovarian cancer cell growth. | Anticancer research 20040101 |
| DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells. | BMC cancer 20040101 |
| Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20040101 |
| Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. | BMC cancer 20040101 |
| Cancer of the endometrium: current aspects of diagnostics and treatment. | World journal of surgical oncology 20040101 |
| Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines. | Anticancer research 20040101 |
| Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. | Oncology research 20040101 |
| Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20040101 |
| Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. | Anticancer research 20040101 |
| Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial. | Acta haematologica 20040101 |
| Role of primary surgery in advanced ovarian cancer. | World journal of surgical oncology 20040101 |
| Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients. | Cancer investigation 20040101 |
| How should we manage patients with 'platinum-sensitive' recurrent ovarian cancer? | Cancer investigation 20040101 |
| Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. | Cancer investigation 20040101 |
| Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. | Cancer investigation 20040101 |
| Foreword--new directions for topotecan in lung cancer treatment. | The oncologist 20040101 |
| Topotecan in the treatment of recurrent small cell lung cancer: an update. | The oncologist 20040101 |
| Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. | The oncologist 20040101 |
| Emerging role of weekly topotecan in recurrent small cell lung cancer. | The oncologist 20040101 |
| Topotecan in the first-line treatment of small cell lung cancer. | The oncologist 20040101 |
| Update on the role of topotecan in the treatment of non-small cell lung cancer. | The oncologist 20040101 |
| [Status report on the chemotherapy of ovarian cancer at special cancer centers in Hungary (2002-2003)]. | Magyar onkologia 20040101 |
| Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. | Anticancer research 20040101 |
| Progress in treatment of small-cell lung cancer: role of CPT-11. | British journal of cancer 20031215 |
| Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. | International journal of cancer 20031210 |
| A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. | Cancer 20031201 |
| Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. | British journal of cancer 20031201 |
| Chemotherapy for ovarian cancer: yesterday, today and tomorrow. | British journal of cancer 20031201 |
| Primary ovarian cancer chemotherapy: current standards of care. | British journal of cancer 20031201 |
| Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. | British journal of cancer 20031201 |
| Docetaxel: promising and novel combinations in ovarian cancer. | British journal of cancer 20031201 |
| Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. | Cancer research 20031201 |
| [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells]. | Ai zheng = Aizheng = Chinese journal of cancer 20031201 |
| [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer]. | Ai zheng = Aizheng = Chinese journal of cancer 20031201 |
| Treatment advances in ovarian cancer. | Cancer nursing 20031201 |
| A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. | British journal of cancer 20031117 |
| Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. | British journal of cancer 20031117 |
| Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at the 7-, 10- and 20-positions. | Bioorganic & medicinal chemistry letters 20031103 |
| Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. | British journal of cancer 20031103 |
| A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. | Investigational new drugs 20031101 |
| An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. | Investigational new drugs 20031101 |
| A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. | Gynecologic oncology 20031101 |
| A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer. | Gynecologic oncology 20031101 |
| The role of breast cancer resistance protein in acute lymphoblastic leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031101 |
| Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma. | Journal of neuro-oncology 20031101 |
| [Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20031101 |
| Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer. | Seminars in oncology nursing 20031101 |
| [Economic assessment of Caelyx versus topotecan in advanced ovarian cancer]. | Bulletin du cancer 20031101 |
| Clinical use of rituximab in haematological malignancies. | British journal of cancer 20031020 |
| Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. | British journal of cancer 20031020 |
| Mechanisms of resistance to topoisomerase I-targeting drugs. | Oncogene 20031020 |
| Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. | Cancer 20031015 |
| Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. | British journal of cancer 20031006 |
| Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. | Cancer chemotherapy and pharmacology 20031001 |
| Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. | Toxicological sciences : an official journal of the Society of Toxicology 20031001 |
| Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. | Annals of oncology : official journal of the European Society for Medical Oncology 20031001 |
| A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. | Leukemia 20031001 |
| Apoptotic pathways of epothilone BMS 310705. | Gynecologic oncology 20031001 |
| Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. | British journal of cancer 20030915 |
| Phase I study of oral topotecan in hematological malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030915 |
| The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. | Cancer chemotherapy and pharmacology 20030901 |
| The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. | Cancer chemotherapy and pharmacology 20030901 |
| Breast cancer resistance protein exports sulfated estrogens but not free estrogens. | Molecular pharmacology 20030901 |
| Interactions of fluorochrome-labeled caspase inhibitors with apoptotic cells: a caution in data interpretation. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030901 |
| Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer. | British journal of cancer 20030901 |
| Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. | British journal of cancer 20030901 |
| Clinical experience with topotecan in relapsed ovarian cancer. | Gynecologic oncology 20030901 |
| First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. | Gynecologic oncology 20030901 |
| The role of topotecan in the treatment of advanced cervical cancer. | Gynecologic oncology 20030901 |
| Treatment options for endometrial cancer: experience with topotecan. | Gynecologic oncology 20030901 |
| Weekly topotecan in the management of ovarian cancer. | Gynecologic oncology 20030901 |
| Optimal sequencing in the treatment of recurrent ovarian cancer. | Gynecologic oncology 20030901 |
| Workshop: options for therapy in ovarian cancer. | Gynecologic oncology 20030901 |
| [Current status of camptothecin derivatives as natural antitumor agents]. | Yao xue xue bao = Acta pharmaceutica Sinica 20030901 |
| Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. | Bioorganic & medicinal chemistry letters 20030818 |
| Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. | British journal of cancer 20030818 |
| Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. | British journal of cancer 20030804 |
| [Topotecan for pediatric patients with resistant and recurrent solid tumors]. | Anales de pediatria (Barcelona, Spain : 2003) 20030801 |
| Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. | Gynecologic oncology 20030801 |
| Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. | Journal of pediatric hematology/oncology 20030801 |
| Expression and functional analyses of breast cancer resistance protein in lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030801 |
| CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030801 |
| Clinical and cellular pharmacology in relation to solid tumours of childhood. | Cancer treatment reviews 20030801 |
| Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. | Gynecologic oncology 20030801 |
| Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors. | Anti-cancer drugs 20030801 |
| The role of topotecan in treating small cell lung cancer: second-line treatment. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Topotecan as first-line therapy for small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Single-agent chemotherapy for non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Combination chemotherapy with topotecan for non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Weekly topotecan in the management of lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Options for first- and second-line therapy in small cell lung cancer--a workshop discussion. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines. | European journal of pharmacology 20030725 |
| Alveolar soft-part sarcoma responding to interferon alpha-2b. | British journal of cancer 20030721 |
| New designs for phase 2 clinical trials. | Blood 20030715 |
| Survival-signaling pathway as a promising target for cancer chemotherapy. | Cancer chemotherapy and pharmacology 20030701 |
| Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. | Anti-cancer drugs 20030701 |
| Influence of the cisplatin hydration schedule on topotecan pharmacokinetics. | European journal of cancer (Oxford, England : 1990) 20030701 |
| Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030701 |
| Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030701 |
| Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030701 |
| A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma. | Yonsei medical journal 20030630 |
| The camptothecins. | Lancet (London, England) 20030628 |
| Oral melphalan as a treatment for platinum-resistant ovarian cancer. | British journal of cancer 20030616 |
| Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. | British journal of cancer 20030616 |
| Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. | British journal of cancer 20030616 |
| Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. | Cancer research 20030615 |
| Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. | Journal of neurovirology 20030601 |
| Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601 |
| Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. | Lung cancer (Amsterdam, Netherlands) 20030601 |
| Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. | Cancer research 20030601 |
| Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. | Anti-cancer drugs 20030601 |
| Second-line chemotherapy for ovarian cancer. | The Lancet. Oncology 20030601 |
| Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. | Annals of oncology : official journal of the European Society for Medical Oncology 20030601 |
| A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030601 |
| Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. | American journal of clinical oncology 20030601 |
| A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. | The journal of obstetrics and gynaecology research 20030601 |
| Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy. | Clinical therapeutics 20030601 |
| Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma. | The Korean journal of internal medicine 20030601 |
| Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. | Journal of medicinal chemistry 20030522 |
| The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. | Life sciences 20030516 |
| Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. | Cancer 20030515 |
| Combined-modality therapy of locally advanced cervical cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515 |
| Developmental chemotherapy and management of recurrent ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515 |
| Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. | Mutation research 20030509 |
| Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. | British journal of cancer 20030506 |
| The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. | International journal of oncology 20030501 |
| Toxicity patterns of cytotoxic drugs. | Investigational new drugs 20030501 |
| ZD9331 in combination with topotecan: phase I and II experience. | Anti-cancer drugs 20030501 |
| Emerging treatments for ovarian cancer. | Expert opinion on emerging drugs 20030501 |
| Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. | British journal of cancer 20030422 |
| Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. | Biochemical pharmacology 20030415 |
| Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. | Journal of pediatric hematology/oncology 20030401 |
| [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance]. | Ai zheng = Aizheng = Chinese journal of cancer 20030401 |
| Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors. | American journal of clinical oncology 20030401 |
| Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins. | Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al 20030401 |
| Population pharmacokinetics/pharmacodynamics relationships of an anticancer drug. | Statistics in medicine 20030330 |
| Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. | British journal of cancer 20030324 |
| Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. | British journal of cancer 20030324 |
| Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030315 |
| Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. | Cancer research 20030315 |
| A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. | Cancer 20030301 |
| Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. | Anti-cancer drugs 20030301 |
| [Second-line Hycamtin in the treatment of lung cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20030301 |
| [A symphony for the camptothecins]. | Bulletin du cancer 20030301 |
| Emerging role of topotecan in first-line therapy of small-cell lung cancer. | Clinical lung cancer 20030301 |
| Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205 |
| A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030201 |
| A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030201 |
| Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. | Gynecologic oncology 20030201 |
| Chemotherapy for small cell lung cancer. | Seminars in oncology 20030201 |
| Chemotherapy for malignant pleural mesothelioma: past results and recent developments. | British journal of cancer 20030127 |
| Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. | Journal of medicinal chemistry 20030116 |
| Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none? | Leukemia research 20030101 |
| A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia. | Leukemia research 20030101 |
| Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. | Critical reviews in oncology/hematology 20030101 |
| Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20030101 |
| Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. | Lung cancer (Amsterdam, Netherlands) 20030101 |
| Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030101 |
| Boosting bioavailability to topotecan: what do we gain? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030101 |
| Recent advances in traditional plant drugs and orchids. | Acta pharmacologica Sinica 20030101 |
| Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. | Molecular cancer therapeutics 20030101 |
| European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030101 |
| The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. | Cancer detection and prevention 20030101 |
| Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. | The oncologist 20030101 |
| A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952. | Neuro-oncology 20030101 |
| [Preclinical studies of concomitant chemoradiation]. | Medicina (Kaunas, Lithuania) 20030101 |
| Current therapies in ovarian cancer. | Cancer investigation 20030101 |
| The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101 |
| A pilot study of topotecan in the treatment of serous carcinoma of the uterus. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101 |
| Modeling plasma and saliva topotecan concentration time course using a population approach. | Oncology research 20030101 |
| High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. | The hematology journal : the official journal of the European Haematology Association 20030101 |
| p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. | Anticancer research 20030101 |
| Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. | BMC cancer 20030101 |
| Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide. | Cell cycle (Georgetown, Tex.) 20030101 |
| Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature. | Clinical and experimental obstetrics & gynecology 20030101 |
| Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. | Anticancer research 20030101 |
| DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. | Cell cycle (Georgetown, Tex.) 20030101 |
| Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. | Cancer investigation 20030101 |
| Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA. | Biopolymers 20030101 |
| Clinical studies of camptothecin and derivatives. | The Alkaloids. Chemistry and biology 20030101 |
| A phase II study of topotecan in patients with relapsed small-cell lung cancer. | Clinical lung cancer 20030101 |
| Topotecan in relapsed small-cell lung cancer: can good things come in small packages? | Clinical lung cancer 20030101 |
| Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101 |
| The role of anthracyclines in second-line therapy of ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101 |
| [Interaction of topotecan-a DNA topoisomerase I inhibitor-with dual-stranded polydeoxyribonucleotides. V. Topotecan is able to cause single- and double-strand breaks in ring superhelical DNA in the absence of enzyme]. | Molekuliarnaia biologiia 20030101 |
| New agents in the treatment of small-cell lung cancer: focus on gemcitabine. | Clinical lung cancer 20030101 |
| Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. | Anticancer research 20030101 |
| Role of weekly paclitaxel in the treatment of advanced ovarian cancer. | Critical reviews in oncology/hematology 20021227 |
| Low levels of ABCG2 expression in adult AML blast samples. | Blood 20021215 |
| Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I. | Journal of biomolecular structure & dynamics 20021201 |
| Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. | Cancer chemotherapy and pharmacology 20021201 |
| A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. | Gynecologic oncology 20021201 |
| Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research 20021201 |
| Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. | Bone marrow transplantation 20021201 |
| Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study. | Journal of neuro-oncology 20021201 |
| New drugs for the treatment of cancer, 1990-2001. | The Israel Medical Association journal : IMAJ 20021201 |
| [Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan]. | Ai zheng = Aizheng = Chinese journal of cancer 20021201 |
| ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies. | European journal of cancer (Oxford, England : 1990) 20021201 |
| The mechanism of topoisomerase I poisoning by a camptothecin analog. | Proceedings of the National Academy of Sciences of the United States of America 20021126 |
| Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. | Journal of medicinal chemistry 20021107 |
| A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20021101 |
| Unexpected pleural effusions in 3 pediatric patients treated with STI-571. | Journal of pediatric hematology/oncology 20021101 |
| A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients. | Gynecologic oncology 20021101 |
| [Own experiences in salvage chemotherapy of ovarian cancer--a preliminary report]. | Ginekologia polska 20021101 |
| Oral cancer treatment: developments in chemotherapy and beyond. | British journal of cancer 20021021 |
| Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. | British journal of cancer 20021021 |
| [Evaluation of topotecan combined with cisplatin in the treatment of small cell lung cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer 20021020 |
| The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. | Biochemical pharmacology 20021015 |
| Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. | Cancer 20021015 |
| First-line chemotherapy for ovarian cancer - the controversy continues. | British journal of cancer 20021007 |
| Platinum drugs in the treatment of non-small-cell lung cancer. | British journal of cancer 20021007 |
| A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. | Cancer 20021001 |
| Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. | Lung cancer (Amsterdam, Netherlands) 20021001 |
| A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. | Annals of oncology : official journal of the European Society for Medical Oncology 20021001 |
| Tumor lysis syndrome in extensive-stage small-cell lung cancer. | American journal of clinical oncology 20021001 |
| Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts. | Anti-cancer drugs 20021001 |
| DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. | Current opinion in investigational drugs (London, England : 2000) 20021001 |
| Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. | Mutation research 20020926 |
| Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. | British journal of cancer 20020923 |
| A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. | Cancer 20020915 |
| A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. | British journal of cancer 20020909 |
| DNA topoisomerase I and II expression in drug resistant germ cell tumours. | British journal of cancer 20020909 |
| Secreted and tumour targeted human carboxylesterase for activation of irinotecan. | British journal of cancer 20020909 |
| Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. | British journal of cancer 20020909 |
| Ovarian cancer: progress and continuing controversies in management. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. | Molecular pharmacology 20020901 |
| Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma. | Urological research 20020901 |
| Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. | Cancer 20020901 |
| SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. | The Prostate 20020901 |
| Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. | The Lancet. Oncology 20020901 |
| Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20020901 |
| VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland. | Clinical lymphoma 20020901 |
| Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. | British journal of cancer 20020827 |
| Carboplatin and topotecan combination and myelosuppression. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020815 |
| Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. | British journal of cancer 20020812 |
| Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. | European journal of cancer (Oxford, England : 1990) 20020801 |
| BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. | Leukemia 20020801 |
| Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20020801 |
| Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies. | American journal of clinical oncology 20020801 |
| Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. | Cancer research 20020801 |
| Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020801 |
| Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. | The Israel Medical Association journal : IMAJ 20020801 |
| Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. | Anti-cancer drugs 20020801 |
| Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. | Leukemia & lymphoma 20020801 |
| [Gemicitabine in the treatment of epithelial ovarian cancer]. | Bulletin du cancer 20020801 |
| Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. | Fundamental & clinical pharmacology 20020801 |
| Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. | International journal of radiation oncology, biology, physics 20020715 |
| Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. | British journal of cancer 20020715 |
| Epithelial ovarian cancer: second and third line chemotherapy (review). | International journal of oncology 20020701 |
| A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. | British journal of cancer 20020701 |
| Boosting bioavailability of topotecan: what do we gain? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701 |
| Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701 |
| Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. | Cancer research 20020701 |
| Urinary and fecal excretion of topotecan in patients with malignant solid tumours. | Cancer chemotherapy and pharmacology 20020701 |
| Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. | International journal of cancer 20020701 |
| Topotecan-induced celluitis-like fixed drug eruption. | Journal of the European Academy of Dermatology and Venereology : JEADV 20020701 |
| Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. | British journal of cancer 20020605 |
| Topotecan is anti-angiogenic in experimental hepatoblastoma. | Journal of pediatric surgery 20020601 |
| Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. | Journal of cancer research and clinical oncology 20020601 |
| Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. | Cancer chemotherapy and pharmacology 20020601 |
| Phase I studies of nogitecan hydrochloride for Japanese. | International journal of clinical oncology 20020601 |
| Troxacitabine-based therapy of refractory leukemia. | Expert review of anticancer therapy 20020601 |
| Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. | Current cancer drug targets 20020601 |
| C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. | Molecular cancer therapeutics 20020601 |
| Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. | British journal of cancer 20020520 |
| [New drugs in bronchial cancer]. | Presse medicale (Paris, France : 1983) 20020511 |
| Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. | Cancer gene therapy 20020501 |
| Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. | Gynecologic oncology 20020501 |
| Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. | Cancer chemotherapy and pharmacology 20020501 |
| Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. | Clinical pharmacology and therapeutics 20020501 |
| No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. | European journal of clinical pharmacology 20020501 |
| Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. | Cancer 20020501 |
| [A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020501 |
| Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. | Cancer chemotherapy and pharmacology 20020501 |
| [Lung carcinoma. An unusual case of survival]. | Recenti progressi in medicina 20020501 |
| [Nogitecan hydrochloride]. | Nihon rinsho. Japanese journal of clinical medicine 20020501 |
| Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. | Leukemia & lymphoma 20020501 |
| [Early results of topotecan therapy in patients with recurrent ovarian cancer]. | Orvosi hetilap 20020421 |
| A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. | Cancer research 20020415 |
| Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. | Gynecologic oncology 20020401 |
| Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. | Gynecologic oncology 20020401 |
| Phase I study of topotecan and radiation therapy in advanced cervical cancer. | Gynecologic oncology 20020401 |
| Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. | Cancer 20020401 |
| Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. | American journal of clinical oncology 20020401 |
| Lung cancer: a review. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020401 |
| Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. | Biochemical pharmacology 20020401 |
| Recurrent ovarian cancer as chronic disease. | Oncology (Williston Park, N.Y.) 20020401 |
| Epithelial ovarian cancer. | Current treatment options in oncology 20020401 |
| Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. | Cancer treatment reviews 20020401 |
| [Killing and proapoptotic effects of topoisomerase I inhibitor on K562 cells]. | Ai zheng = Aizheng = Chinese journal of cancer 20020401 |
| [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer]. | Ai zheng = Aizheng = Chinese journal of cancer 20020401 |
| Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. | Molecular cancer therapeutics 20020401 |
| Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315 |
| Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315 |
| Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. | Cancer research 20020315 |
| Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. | Cytokine 20020307 |
| Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. | British journal of cancer 20020304 |
| Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. | International journal of cancer 20020301 |
| Chemotherapy and pregnancy. | Clinical obstetrics and gynecology 20020301 |
| Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. | Journal of pediatric surgery 20020301 |
| Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination. | Mutagenesis 20020301 |
| Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020301 |
| A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020301 |
| Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020301 |
| Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors. | Biochemical pharmacology 20020301 |
| Topotecan and the development of scleroderma or a scleroderma-like illness. | Arthritis and rheumatism 20020301 |
| Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. | Japanese journal of cancer research : Gann 20020301 |
| Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20020301 |
| Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. | Annals of oncology : official journal of the European Society for Medical Oncology 20020301 |
| Neutrophilic eccrine hidradenitis secondary to topotecan. | The Journal of dermatological treatment 20020301 |
| The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine. | Biochemical pharmacology 20020215 |
| Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation. | International journal of radiation biology 20020201 |
| Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. | European journal of cancer (Oxford, England : 1990) 20020201 |
| Individual adaptive dosing of topotecan in ovarian cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020201 |
| The role of gemcitabine-based doublets in the management of ovarian carcinoma. | Seminars in oncology 20020201 |
| Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). | Seminars in oncology 20020201 |
| Future directions in the treatment of ovarian cancer. | Seminars in oncology 20020201 |
| [Developed new agents for lung cancer]. | Nihon Geka Gakkai zasshi 20020201 |
| Clinical trials using irinotecan. | Journal of pediatric hematology/oncology 20020201 |
| Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. | Journal of pediatric hematology/oncology 20020201 |
| Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. | Investigational new drugs 20020201 |
| Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). | Clinical lung cancer 20020201 |
| Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. | Journal of medicinal chemistry 20020131 |
| Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. | The Journal of biological chemistry 20020125 |
| Cell-based assays for identification of novel double-strand break-inducing agents. | Journal of the National Cancer Institute 20020116 |
| X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. | Cancer research 20020115 |
| S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. | The Journal of biological chemistry 20020111 |
| Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. | British journal of cancer 20020107 |
| Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020105 |
| The use of oral cytotoxic and cytostatic drugs in cancer treatment. | European journal of cancer (Oxford, England : 1990) 20020101 |
| A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20020101 |
| Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. | European journal of cancer (Oxford, England : 1990) 20020101 |
| Phase I study of combination topotecan and carboplatin in pediatric solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101 |
| Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20020101 |
| A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study. | Cancer investigation 20020101 |
| Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study. | Anti-cancer drugs 20020101 |
| Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. | Drugs & aging 20020101 |
| New approaches to the treatment of myelodysplasia. | The oncologist 20020101 |
| An HIV treatment the world may never see. | Positively aware : the monthly journal of the Test Positive Aware Network 20020101 |
| Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. | Journal of the Society for Gynecologic Investigation 20020101 |
| Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials. | European journal of gynaecological oncology 20020101 |
| Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma. | Medical oncology (Northwood, London, England) 20020101 |
| Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? | The oncologist 20020101 |
| [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. III. Binding at the minor groove]. | Molekuliarnaia biologiia 20020101 |
| Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. | Klinische Padiatrie 20020101 |
| Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study. | Oncology reports 20020101 |
| Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? | The oncologist 20020101 |
| Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies. | Cancer investigation 20020101 |
| DNA binding induces conformational transition within human DNA topoisomerase I in solution. | Biopolymers 20020101 |
| The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. | European journal of gynaecological oncology 20020101 |
| Camptothecins: a review of their chemotherapeutic potential. | Drugs 20020101 |
| Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. | Drugs 20020101 |
| Update on the role of topotecan in the treatment of recurrent ovarian cancer. | The oncologist 20020101 |
| Management of treatment-related toxicity in advanced ovarian cancer. | The oncologist 20020101 |
| Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. | The oncologist 20020101 |
| Update on the treatment of cervical and uterine carcinoma: focus on topotecan. | The oncologist 20020101 |
| Emerging role of topotecan in front-line treatment of carcinoma of the ovary. | The oncologist 20020101 |
| Current status and perspectives in the development of camptothecins. | Current pharmaceutical design 20020101 |
| Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study. | Oncology reports 20020101 |
| [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA]. | Molekuliarnaia biologiia 20020101 |
| Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. | Journal of experimental therapeutics & oncology 20020101 |
| Oral cytotoxic drugs. | I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101 |
| Multiple myeloma and its treatment. | Clinical journal of oncology nursing 20020101 |
| Early detection and successful treatment of drug-induced pneumonitis with corticosteroids. | Cancer investigation 20020101 |
| A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. | The oncologist 20020101 |
| Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. | The oncologist 20020101 |
| [4th National Conference of the Italian Association of Medical Oncology. From research to clinical practice: the role of topotecan in oncology]. | Tumori 20020101 |
| Topoisomerase I interactive agents. | Cancer chemotherapy and biological response modifiers 20020101 |
| First-line chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20020101 |
| Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. | Blood 20011215 |
| Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. | Toxicology in vitro : an international journal published in association with BIBRA 20011201 |
| The Cockayne syndrome group B DNA repair protein as an anti-cancer target. | International journal of oncology 20011201 |
| Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. | The Journal of pharmacology and experimental therapeutics 20011201 |
| Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20011201 |
| Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. | Journal of pediatric surgery 20011201 |
| A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. | Gynecologic oncology 20011201 |
| Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. | Gynecologic oncology 20011201 |
| Treatment of advanced ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20011201 |
| Phase III data on Caelyx in ovarian cancer. | European journal of cancer (Oxford, England : 1990) 20011201 |
| Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20011201 |
| Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. | American journal of hematology 20011201 |
| Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin). | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20011201 |
| The role of half-transporters in multidrug resistance. | Journal of bioenergetics and biomembranes 20011201 |
| Quantitation of camptothecin and related compounds. | Journal of chromatography. B, Biomedical sciences and applications 20011125 |
| Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity. | Journal of chromatography. B, Biomedical sciences and applications 20011125 |
| Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. | Journal of medicinal chemistry 20011122 |
| Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. | Biochemical and biophysical research communications 20011109 |
| Efficacy of topotecan treatment on an experimental model of transient evoked otoacoustic emissions. | International journal of pediatric otorhinolaryngology 20011101 |
| The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. | International journal of oncology 20011101 |
| Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. | Gynecologic oncology 20011101 |
| A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. | Gynecologic oncology 20011101 |
| Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. | Molecular pharmacology 20011101 |
| Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. | British journal of haematology 20011101 |
| A phase I and pharmacokinetic study of intraperitoneal topotecan. | British journal of cancer 20011101 |
| Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan. | Medical and pediatric oncology 20011101 |
| A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. | Annals of oncology : official journal of the European Society for Medical Oncology 20011101 |
| [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20011101 |
| A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development. | Pharmacology & toxicology 20011101 |
| Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. | Molecular cancer therapeutics 20011101 |
| Second-line chemotherapy for small-cell lung cancer: a review. | Clinical lung cancer 20011101 |
| High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. | Cancer 20011015 |
| Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011015 |
| Downregulation of topoisomerase I in differentiating human intestinal epithelial cells. | International journal of cancer 20011015 |
| A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20011001 |
| Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011001 |
| Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. | Cancer research 20011001 |
| Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011001 |
| A new case of isolated del(12)(q15q22) in myelodysplastic syndrome. | Cancer genetics and cytogenetics 20011001 |
| Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. | Bone marrow transplantation 20011001 |
| Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. | British journal of cancer 20011001 |
| Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. | Journal of medicinal chemistry 20010927 |
| Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. | Cancer research 20010915 |
| High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. | Gynecologic oncology 20010901 |
| Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010901 |
| Therapeutic options for acute myelogenous leukemia. | Cancer 20010901 |
| A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. | Cancer 20010901 |
| Chemotherapy as treatment of primary and recurrent small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20010901 |
| Synergistic interaction between topotecan and microtubule-interfering agents. | Cancer chemotherapy and pharmacology 20010901 |
| Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. | Bone marrow transplantation 20010901 |
| Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells. | Bone marrow transplantation 20010901 |
| Recent advances in the treatment of epithelial ovarian cancer. | Expert opinion on investigational drugs 20010901 |
| Resistance to topoisomerase poisons due to loss of DNA mismatch repair. | International journal of cancer 20010815 |
| A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. | Cancer research 20010815 |
| Clonal heterogeneity of p53 mutations in ovarian cancer. | International journal of oncology 20010801 |
| Phase I clinical trial of weekly combined topotecan and irinotecan. | American journal of clinical oncology 20010801 |
| Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. | Journal of pediatric surgery 20010801 |
| Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801 |
| Pharmacodynamic model of topotecan-induced time course of neutropenia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010801 |
| A mutation in subunit B of the DNA polymerase alpha-primase complex from Novikoff hepatoma cells concomitant with a conformational change and abnormal catalytic properties of the DNA polymerase alpha-primase complex. | Molecular carcinogenesis 20010801 |
| Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20010801 |
| Management of small cell lung cancer. | Expert review of anticancer therapy 20010801 |
| Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. | International journal of cancer 20010715 |
| Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010715 |
| A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. | Cancer 20010715 |
| CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. | Oncogene 20010712 |
| Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. | International journal of radiation oncology, biology, physics 20010701 |
| UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice. | International journal of oncology 20010701 |
| Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. | Lung cancer (Amsterdam, Netherlands) 20010701 |
| Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010701 |
| Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. | Cancer chemotherapy and pharmacology 20010701 |
| Topoisomerase I inhibitors in the treatment of head and neck cancer. | Oncology (Williston Park, N.Y.) 20010701 |
| Advances in the management of epithelial ovarian cancer. | The Journal of reproductive medicine 20010701 |
| Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20010701 |
| Surgery, radiotherapy, and chemotherapy for esophageal carcinoma. | Current opinion in gastroenterology 20010701 |
| Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. | International journal of oncology 20010601 |
| Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance. | American journal of clinical oncology 20010601 |
| Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. | Onkologie 20010601 |
| Oligodendroglial ganglioglioma with anaplastic features arising from the thalamus. | Pediatric neurosurgery 20010601 |
| Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. | Cancer chemotherapy and pharmacology 20010601 |
| Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20010601 |
| Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515 |
| Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. | Cancer research 20010515 |
| Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues. | Journal of medicinal chemistry 20010510 |
| Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20010501 |
| Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. | Gynecologic oncology 20010501 |
| Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer. | Gynecologic oncology 20010501 |
| A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. | British journal of cancer 20010501 |
| Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010501 |
| A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. | Gynecologic oncology 20010501 |
| Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. | Journal of pediatric hematology/oncology 20010501 |
| Role of topoisomerase I inhibitors in small-cell lung cancer. | Clinical lung cancer 20010501 |
| Topoisomerase I inhibitors in the combined modality therapy of lung cancer. | Clinical lung cancer 20010501 |
| Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415 |
| Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. | Cancer research 20010415 |
| A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. | Blood 20010401 |
| Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010401 |
| Determination of topotecan by ELISA. | Biological & pharmaceutical bulletin 20010401 |
| Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. | Cancer research 20010401 |
| Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. | Cancer research 20010401 |
| Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. | Cancer research 20010401 |
| Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. | British journal of cancer 20010401 |
| Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010401 |
| The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia. | Haematologica 20010401 |
| Antitumor activity of XR5944, a novel and potent topoisomerase poison. | Anti-cancer drugs 20010401 |
| New agents for induction and postremission therapy of acute myeloid leukemia. | Leukemia 20010401 |
| Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. | World journal of urology 20010401 |
| Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20010401 |
| Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. | Seminars in oncology 20010401 |
| Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010315 |
| Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. | Journal of controlled release : official journal of the Controlled Release Society 20010312 |
| Topoisomerase I targeting agents in small-cell lung cancer. | Current oncology reports 20010301 |
| Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. | Cancer research 20010301 |
| Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells. | Gene therapy 20010301 |
| Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. | Cancer chemotherapy and pharmacology 20010301 |
| Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. | Expert opinion on pharmacotherapy 20010301 |
| The epidermal growth factor receptor as a target for cancer therapy. | Endocrine-related cancer 20010301 |
| [Evaluation of quality of life in patients with advanced colorectal cancer treated with topotecan]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20010301 |
| [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20010301 |
| The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. | Sarcoma 20010301 |
| Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215 |
| Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215 |
| P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. | Cancer research 20010215 |
| Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin. | Bioorganic & medicinal chemistry letters 20010212 |
| Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. | Biochemical and biophysical research communications 20010209 |
| Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial. | Gynecologic oncology 20010201 |
| Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response. | Cancer 20010201 |
| Selective drug resistant human osteosarcoma cell lines. | Clinical orthopaedics and related research 20010201 |
| P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. | Cancer research 20010201 |
| Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). | American journal of clinical oncology 20010201 |
| Clear cell carcinoma of the ovary: a remarkable case. | American journal of clinical oncology 20010201 |
| Modulation of camptothecin analogs in the treatment of cancer: a review. | Anti-cancer drugs 20010201 |
| Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. | Japanese journal of clinical oncology 20010201 |
| Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. | European journal of pharmacology 20010119 |
| The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. | Cancer research 20010115 |
| ICE bioassay. Isolating in vivo complexes of enzyme to DNA. | Methods in molecular biology (Clifton, N.J.) 20010101 |
| Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010101 |
| Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. | Gynecologic oncology 20010101 |
| Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan. | Biochemical pharmacology 20010101 |
| Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report. | Haematologica 20010101 |
| Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. | Oncology 20010101 |
| The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. | Critical reviews in oncology/hematology 20010101 |
| Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010101 |
| Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. | Cancer chemotherapy and pharmacology 20010101 |
| Treatment of extensive stage small cell lung cancer. | Cancer treatment and research 20010101 |
| The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. | Annals of oncology : official journal of the European Society for Medical Oncology 20010101 |
| Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. | Cancer chemotherapy and pharmacology 20010101 |
| Current treatment for ovarian cancer. | Expert opinion on pharmacotherapy 20010101 |
| Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents. | Cancer journal (Sudbury, Mass.) 20010101 |
| [Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution]. | Molekuliarnaia biologiia 20010101 |
| [Interaction of topotecan--a DNA topoisomerase I inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan]. | Molekuliarnaia biologiia 20010101 |
| A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). | Cancer investigation 20010101 |
| Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model. | Journal of pediatric hematology/oncology 20010101 |
| Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20010101 |
| The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. | Arthritis research 20010101 |
| Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. | Lung cancer (Amsterdam, Netherlands) 20010101 |
| Novel therapies in lung cancer management. An update on the role of topotecan. | Oncology 20010101 |
| Current standards of care in small-cell and non-small-cell lung cancer. | Oncology 20010101 |
| New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. | Oncology 20010101 |
| A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. | Oncology 20010101 |
| Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer. | Oncology 20010101 |
| Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. | Oncology 20010101 |
| Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy. | Oncology 20010101 |
| Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. | Oncology 20010101 |
| Future role of topotecan in the treatment of lung cancer. | Oncology 20010101 |
| Topoisomerase I interactive agents. | Cancer chemotherapy and biological response modifiers 20010101 |
| Intravenous bolus topotecan in patients with myelodysplastic syndrome. | Leukemia & lymphoma 20010101 |
| A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. | Health technology assessment (Winchester, England) 20010101 |
| A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. | Oncology 20010101 |
| Controversies in the management of brain metastases: the role of chemotherapy. | Forum (Genoa, Italy) 20010101 |
| Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20010101 |
| The development of camptothecin analogs in childhood cancers. | The oncologist 20010101 |
| Therapeutic management of refractory or relapsed primary central nervous system lymphomas. | Annals of hematology 20010101 |
| Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. | Anticancer research 20010101 |
| Long time therapy with topotecan in patients with recurrence of ovarian carcinoma. | Anticancer research 20010101 |
| Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan. | European journal of gynaecological oncology 20010101 |
| Nursing considerations for managing topotecan-related hematologic side effects. | Clinical journal of oncology nursing 20010101 |
| [3rd National Congress of Medical Oncology. Issues in Gynecologic Oncology. Naples, November 7, 2000]. | Tumori 20010101 |
| The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. | Journal of medicinal chemistry 20001019 |
| Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. | American journal of clinical oncology 20000801 |
| Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. | Clinical cancer research : an official journal of the American Association for Cancer Research 20000701 |
| Phase II study of oral topotecan in advanced non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20000301 |
| An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. | Cancer research 20000201 |
| Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. | Leukemia 20000101 |
| Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. | Antimicrobial agents and chemotherapy 19991201 |
| Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. | Cancer research 19991201 |
| Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. | Oncology 19990101 |
| [Topotecan: a new field of use]. | Tumori 19990101 |
| Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. | Anti-cancer drugs 19980601 |
| Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. | Antimicrobial agents and chemotherapy 19970501 |
| An overview of the clinical pharmacology of topotecan. | Seminars in oncology 19970201 |
| Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. | Investigational new drugs 19970101 |
| Clinical pharmacokinetics of topotecan. | Clinical pharmacokinetics 19960801 |
| Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. | Journal of medicinal chemistry 19930903 |
| Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. | Cancer research 19930615 |
| Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. | Proceedings of the National Academy of Sciences of the United States of America 19930301 |